<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2204245188
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ZAVICEFTA 2 g/0.5 g Vial
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CEFTAZIDIME,AVIBACTAM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        2,0.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        g
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        4537.50
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ACS DOBFAR SPA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ACS DOBFAR SPA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2657]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Pfizer Saudi Trading
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Pfizer Ireland Pharmaceuticals
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01DD
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Zavicefta is</strong></p><p>Zavicefta is an antibiotic medicine that contains two active substances ceftazidime and avibactam.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ceftazidime belongs to the group of antibiotics called &ldquo;cephalosporins&rdquo;. It can kill many types of bacteria.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Avibactam is a &ldquo;beta-lactamase inhibitor&rdquo; that helps ceftazidime kill some bacteria that it cannot kill on its own.</p><p>&nbsp;</p><p><strong>What Zavicefta is used for</strong></p><p>Zavicefta is used in adults and paediatric patients from birth to treat:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infections of the stomach and gut (abdomen)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infections of the bladder or kidneys called &ldquo;urinary tract infections&rdquo;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an infection of the lungs called &ldquo;pneumonia&rdquo;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infections caused by bacteria that other antibiotics may not be able to kill</p><p>&nbsp;</p><p>Zavicefta is used in adults to treat infection of the blood associated with infections of the abdomen, urinary tract, or pneumonia.</p><p>&nbsp;</p><p><strong>How Zavicefta works</strong></p><p>Zavicefta works by killing certain types of bacteria, which can cause serious infections.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Zavicefta if:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are allergic to ceftazidime, avibactam or any of the other ingredients of this medicine (listed in section 6)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are allergic to other cephalosporin antibiotics</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have ever had a severe allergic reaction to other antibiotics belonging to the penicillin or carbapenem groups</p><p>&nbsp;</p><p>Do not use Zavicefta if any of the above apply to you. If you are not sure, talk to your doctor or nurse before using Zavicefta.</p><p>&nbsp;</p><p><strong>Warnings and precautions </strong></p><p>Talk to your doctor or nurse before using Zavicefta if:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have ever had any allergic reaction (even if only a skin rash) to other antibiotics belonging to the penicillin or carbapenem groups</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have kidney problems - your doctor may give you a lower dose to make sure you don&rsquo;t get too much medicine. This could cause symptoms such as fits (see section <strong>If you use more Zavicefta than you should</strong>)</p><p>If any of the above apply to you (or you are not sure), talk to your doctor or nurse before using Zavicefta.</p><p>&nbsp;</p><p>Talk to your doctor or nurse if you suffer from diarrhoea during your treatment.</p><p>&nbsp;</p><p><u>Other infections</u></p><p>There is a small possibility that you may get a different infection caused by another bacteria during or after treatment with Zavicefta. These include thrush (fungal infections of the mouth or genital area).</p><p>&nbsp;</p><p><u>Lab tests</u></p><p>Tell your doctor that you are taking Zavicefta if you are going to have any tests. This is because you may get an abnormal result with a test called &ldquo;DAGT&rdquo; or &ldquo;Coombs&rdquo;. This test looks for antibodies that fight against your red blood cells.</p><p>&nbsp;</p><p>Zavicefta can also affect the results of some urine tests for sugar. Tell the person taking the sample that you have been given Zavicefta.</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and Zavicefta</strong></p><p>Tell your doctor or nurse if you are using, have recently used or might use any other medicines.</p><p>&nbsp;</p><p>Talk to your doctor before using Zavicefta if you are taking any of the following medicines:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an antibiotic called chloramphenicol</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a type of antibiotic called an aminoglycoside &ndash; such as gentamicin, tobramycin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a water tablet called furosemide</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a medicine for gout called probenecid</p><p>&nbsp;</p><p>Tell your doctor before using Zavicefta if any of the above apply to you.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding </strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before using this medicine.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Zavicefta may make you feel dizzy. This may affect you being able to drive, use tools or machines.</p><p><strong>&nbsp;</strong></p><p><strong>Zavicefta contains sodium</strong></p><p>This medicine contains sodium (main component of cooking/table salt).</p><p>Talk to your doctor or pharmacist if you need 3 or more vials daily for a prolonged period, especially if you have been advised to have a low salt (sodium) diet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Zavicefta will be given to you by a doctor or a nurse.</p><p>&nbsp;</p><p><strong>How much to use</strong></p><p>The recommended dose for adults is one vial (2&nbsp;g of ceftazidime and 0.5 g&nbsp;of avibactam), every 8&nbsp;hours. The dose for paediatric patients from birth will be calculated by the doctor based on the weight and age of the child.</p><p>&nbsp;</p><p>It is given as a drip into a vein &ndash; this will normally take about 2 hours.</p><p>&nbsp;</p><p>A course of treatment usually lasts from 5 to up to 14 days, depending on the type of infection you have and how you respond to treatment.</p><p>&nbsp;</p><p><u>People with kidney problems</u></p><p>If you have kidney problems your doctor may lower your dose. This is because Zavicefta is removed from your body by the kidneys.</p><p>&nbsp;</p><p><strong>If you use more Zavicefta than you should</strong></p><p>Zavicefta will be given to you by a doctor or a nurse, so it is unlikely you will be given the wrong dose. However, if you have side effects or think you have been given too much Zavicefta, tell your doctor or nurse straight away. If you have too much Zavicefta it could have an effect on the brain and cause fits or coma.</p><p>&nbsp;</p><p><strong>If you miss a dose of Zavicefta</strong></p><p>If you think you have missed a dose, tell your doctor or nurse straight away.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. The following side effects may happen with this medicine:</p><p>&nbsp;</p><p><strong>Serious side effects</strong></p><p>Tell your doctor straight away if you notice any of the following serious side effects - you may need urgent medical treatment:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe allergic reactions &ndash; signs include sudden swelling of your lips, face, throat or tongue, a severe rash or other severe skin reactions, difficulty swallowing or breathing, or sudden chest pain (which may be a sign of Kounis syndrome). These reactions may be life-threatening.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea that keeps getting worse or does not go away, or stools that contains blood or mucus &ndash; this may happen during or after treatment is stopped with Zavicefta. If this happens do not take medicines that stop or slow bowel movement.</p><p>Tell your doctor straight away if you notice any of the serious side effects above.</p><p><strong>&nbsp;</strong></p><p>Other side effects</p><p>Tell your doctor or nurse if you notice any of the following side effects:</p><p><strong>&nbsp;</strong></p><p><strong>Very common: </strong>(may affect more than 1 in 10 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal result with a test called &ldquo;DAGT&rdquo; or &ldquo;Coombs&rdquo;. This test looks for antibodies that fight against your red blood cells. It is possible that this could cause anaemia (which may make you feel tired) and jaundice (yellowing of the skin and eyes)</p><p><strong>&nbsp;</strong></p><p><strong>Common: </strong>(may affect up to 1 in 10 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fungal infections, including those of the mouth and vagina</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; change in the number of some types of blood cells (called &ldquo;eosinophils&rdquo; and &ldquo;thrombocytes&rdquo;) &ndash; shown in blood tests</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling dizzy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick (nausea) or being sick (vomiting)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase in the amount of some enzymes produced by your liver - shown in blood tests</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; raised itchy skin rash (&ldquo;hives&rdquo;)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itchiness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; redness, pain or swelling where Zavicefta was given into a vein</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever</p><p>&nbsp;</p><p><strong>Uncommon: </strong>(may affect up to 1 in 100 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase in the number of a type of blood cell (called &ldquo;lymphocytes&rdquo;) &ndash; shown in blood tests</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decrease in the number of some types of blood cells (called &ldquo;leucocytes&rdquo;) - shown in blood tests</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tingling or numbness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bad taste in your mouth</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an increase in the level of some types of substances in your blood (called &ldquo;creatinine&rdquo; and &ldquo;urea&rdquo;). These show how well your kidneys are working.</p><p><strong>&nbsp;</strong></p><p><strong>Very rare: </strong>(may affect up to 1 in 10,000 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling in a part of the kidney that causes a reduction in its normal working function</p><p><strong>&nbsp;</strong></p><p><strong>Not known</strong>: (frequency cannot be estimated from the available data)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; significant decrease in the type of white blood cells used to fight infection - shown in blood tests</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decrease in the number of red blood cells (haemolytic anaemia) &ndash; shown in blood tests</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe allergic reaction (see <strong>Serious side effects</strong>, above)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; yellowing of the whites of the eyes or skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden onset of a severe rash or blistering or peeling skin, possibly accompanied by a high fever or joint pain (these may be signs of more serious medical conditions such as toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme or a condition known as DRESS, Drug Reaction with Eosinophilia and Systemic Symptoms)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling under the skin, particularly lips and around the eyes</p><p><strong>&nbsp;</strong></p><p>Tell your doctor or nurse if you notice any of the side effects listed above.</p><p><strong>&nbsp;</strong></p><p>Reporting of side effects</p><p>If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre (NPC)</p><ul><li>Call center: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Store Below 30&deg;C.</p><p>&nbsp;</p><p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the container. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p><u>Shelf-life of Dry powder:</u> 3 years.</p><p>&nbsp;</p><p><u>Shelf-life a</u><u>fter reconstitution:</u> The reconstituted vial should be used immediately.</p><p>&nbsp;</p><p><u>Shelf-life a</u><u>fter dilution</u></p><p>&nbsp;</p><p><em>Infusion bags</em></p><p>If the intravenous solution is prepared with diluents listed in section 6.6 (ceftazidime concentration 8&nbsp;mg/mL), the chemical and physical in-use stability has been demonstrated (from initial vial puncture) for up to 12&nbsp;hours at 2&nbsp;‑&nbsp;8&deg;C, followed by up to 4&nbsp;hours at not more than 25&deg;C.</p><p>&nbsp;</p><p>If the intravenous solution is prepared with diluents listed in section 6.6 (ceftazidime concentration &gt;&nbsp;8&nbsp;mg/mL to 40&nbsp;mg/mL), the chemical and physical in-use stability has been demonstrated (from initial vial puncture) for up to 4&nbsp;hours at not more than 25&deg;C.</p><p>&nbsp;</p><p>From a microbiological point of view, the medicinal product should be used immediately, unless reconstitution and dilution have taken place in controlled and validated aseptic conditions. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and must not exceed those stated above.</p><p>&nbsp;</p><p><em>Infusion syringes</em></p><p>If the intravenous solution is prepared with diluents listed in section 6.6 (ceftazidime concentration &ge;&nbsp;8&nbsp;mg/mL to 40&nbsp;mg/mL), the chemical and physical in-use stability has been demonstrated (from initial vial puncture) for up to 6&nbsp;hours at not more than 25&deg;C.</p><p>&nbsp;</p><p>From a microbiological point of view, the medicinal product should be used immediately unless reconstitution and dilution have taken place in controlled and validated aseptic conditions. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and must not exceed 6 hours at not more than 25&deg;C.</p><p>&nbsp;</p><p>Zavicefta (ceftazidime/avibactam) is a combination product; each vial contains 2 g of ceftazidime and 0.5&nbsp;g of avibactam in a fixed 4:1 ratio. Dosage recommendations are based on the ceftazidime component only.</p><p>&nbsp;</p><p>Standard aseptic techniques should be used for solution preparation and administration. Doses may be prepared in an appropriately sized infusion bag or infusion syringe.</p><p>&nbsp;</p><p>The resulting solution should be administered over 120 minutes.</p><p>&nbsp;</p><p>Each vial is for single use only.</p><p>&nbsp;</p><p>Any unused product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p><p>The total time interval between starting reconstitution and completing preparation of the intravenous infusion should not exceed 30 minutes.</p><p><u>&nbsp;</u></p><p><u>Instructions for preparing adult and paediatric doses in INFUSION BAG or in INFUSION SYRINGE</u><u>:</u></p><p><u>&nbsp;</u></p><p>NOTE: The following procedure describes the steps to prepare an infusion solution with a final concentration of 8-40 mg/mL of ceftazidime. All calculations should be completed prior to initiating these steps.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>For paediatric patients 3 to 12 months of age</strong>, detailed steps to prepare a 20 mg/mL concentration (sufficient for most scenarios) are provided below.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>For paediatric patients from birth (including preterm) to &lt; 3 months of age</strong>, detailed steps to prepare a <strong>10 mg/mL concentration</strong> (sufficient for most scenarios) are provided below.</p><p>&nbsp;</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prepare the <strong>reconstituted solution</strong> (<strong>167.3 mg/mL</strong> of ceftazidime):</p><p>a)&nbsp;&nbsp;&nbsp;&nbsp; Insert the syringe needle through the vial closure and inject 10&nbsp;mL of sterile water for injections.</p><p>b)&nbsp;&nbsp;&nbsp;&nbsp; Withdraw the needle and shake the vial to give a clear solution.</p><p>c)&nbsp;&nbsp;&nbsp;&nbsp; Insert a gas relief needle through the vial closure<strong> after</strong> the product has dissolved to relieve the internal pressure (this is important to preserve product sterility).</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prepare the <strong>final solution</strong> for infusion (final concentration must be <strong>8-40 mg/mL</strong> of ceftazidime):</p><p>a)&nbsp;&nbsp;&nbsp;&nbsp; Infusion bag: Further dilute the reconstituted solution by transferring an appropriately calculated volume of the reconstituted solution to an infusion bag containing any of the following: sodium chloride 9 mg/mL (0.9%) solution for injection, dextrose 50 mg/mL (5%) solution for injection, or Lactated Ringer&rsquo;s solution.</p><p>b)&nbsp;&nbsp;&nbsp;&nbsp; Infusion syringe: Further dilute the reconstituted solution by transferring an appropriately calculated volume of the reconstituted solution combined with a sufficient volume of diluent (sodium chloride 9 mg/mL (0.9%) solution for injection or dextrose 50 mg/mL (5%) solution for injection) to an infusion syringe.</p><p>&nbsp;</p><p>Refer to the Table below.</p><p>&nbsp;</p><p>Preparation of Zavicefta for adult and paediatric doses in INFUSION BAG or in INFUSION SYRINGE.</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Zavicefta</strong></p><p><strong>Dose (ceftazidime)<sup>1</sup></strong></p></td><td style="vertical-align:top"><p><strong>Volume to withdraw from reconstituted vial</strong></p></td><td style="vertical-align:top"><p><strong>Final volume after dilution in infusion bag<sup>2</sup></strong></p></td><td style="vertical-align:top"><p><strong>Final volume in infusion syringe<sup>3</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>2 g</p></td><td><p>Entire contents (approximately 12 mL)</p></td><td><p>50 mL to 250 mL</p></td><td><p>50 mL</p></td></tr><tr><td style="vertical-align:top"><p>1 g</p></td><td><p>6 mL</p></td><td><p>25 mL to 125 mL</p></td><td><p>25 mL to 50 mL</p></td></tr><tr><td style="vertical-align:top"><p>0.75 g</p></td><td><p>4.5 mL</p></td><td><p>19 mL to 93 mL</p></td><td><p>19 mL to 50 mL</p></td></tr><tr><td style="vertical-align:top"><p>All other doses</p></td><td><p>Volume (mL) calculated based on dose required:</p><p>&nbsp;</p><p><strong>Dose (mg ceftazidime) </strong><strong>&divide; 167.3 mg/mL ceftazidime</strong></p><p>&nbsp;</p></td><td><p>Volume (mL) will vary based on infusion bag size availability and preferred final concentration</p><p>(must be 8-40 mg/mL of ceftazidime)</p></td><td><p>Volume (mL) will vary based on infusion syringe size availability and preferred final concentration</p><p>(must be 8-40 mg/mL of ceftazidime)</p></td></tr></tbody></table><p><sup>1 </sup>Based on ceftazidime component only.<sup> </sup></p><p><sup>2</sup> Dilute to final ceftazidime concentration of 8&nbsp;mg/mL for in-use stability up to 12&nbsp;hours at 2&nbsp;-&nbsp;8&deg;C, followed by up to 4&nbsp;hours at not more than 25&deg;C (i.e. dilute 2&nbsp;g dose of ceftazidime in 250&nbsp;mL, 1&nbsp;g dose of ceftazidime in 125&nbsp;mL, 0.75&nbsp;g dose of ceftazidime in 93&nbsp;mL, etc.). All other ceftazidime concentrations (&gt;&nbsp;8&nbsp;mg/mL to 40&nbsp;mg/mL) have in-use stability up to 4&nbsp;hours at not more than 25&deg;C.</p><p><sup>3</sup> Dilute to final ceftazidime concentration &ge; 8&nbsp;mg/mL to 40 mg/mL for in-use stability up to 6&nbsp;hours at not more than 25&deg;C.</p><p>&nbsp;</p><p><u>Paediatric patients 3 to 12 months of age</u></p><p><em>&nbsp;</em></p><p>NOTE: The following procedure describes the steps to prepare an infusion solution with a final concentration of 20 mg/mL of ceftazidime (sufficient for most scenarios). Alternative concentrations may be prepared, but must have a final concentration range of 8-40 mg/mL of ceftazidime.</p><p>&nbsp;</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp; Prepare the <strong>reconstituted solution</strong> (<strong>167.3 mg/mL</strong> of ceftazidime):</p><p>a)&nbsp;&nbsp;&nbsp;&nbsp; Insert the syringe needle through the vial closure and inject 10&nbsp;mL of sterile water for injections.</p><p>b)&nbsp;&nbsp;&nbsp;&nbsp; Withdraw the needle and shake the vial to give a clear solution.</p><p>c)&nbsp;&nbsp;&nbsp;&nbsp; Insert a gas relief needle through the vial closure <strong>after</strong> the product has dissolved to relieve the internal pressure (this is important to preserve product sterility).</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp; Prepare the <strong>final solution</strong> for infusion to a final concentration of <strong>20 mg/mL</strong> of ceftazidime:</p><p>a)&nbsp;&nbsp;&nbsp;&nbsp; Further dilute the reconstituted solution by transferring an appropriately calculated volume of the reconstituted solution combined with a sufficient volume of diluent (sodium chloride 9&nbsp;mg/mL (0.9%) solution for injection or dextrose 50&nbsp;mg/mL (5%) solution for injection) to an infusion syringe.</p><p>b)&nbsp;&nbsp;&nbsp;&nbsp; Refer to the Tables below to confirm the calculations. Values shown are approximate as it may be necessary to round to the nearest graduation mark of an appropriately sized syringe.</p><p>Note that the tables are NOT inclusive of all possible calculated doses but may be utilised to estimate the approximate volume to verify the calculation.</p><p>&nbsp;</p><p>Preparation of Zavicefta (final concentration of 20 mg/mL of ceftazidime) in paediatric patients 3 to 12&nbsp;months of age with creatinine clearance (CrCL) &gt;&nbsp;50&nbsp;mL/min/1.73 m<sup>2</sup></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td><p><strong>Age and Zavicefta Dose (mg/kg)<sup>1</sup></strong></p></td><td><p><strong>Weight (kg)</strong></p></td><td><p><strong>Dose </strong></p><p><strong>(mg ceftazidime)</strong></p></td><td><p><strong>Volume of reconstituted solution to be withdrawn from vial </strong></p><p><strong>(mL)</strong></p></td><td><p><strong>Volume of diluent to add for mixing (mL)</strong></p></td></tr></thead><tbody><tr><td rowspan="8"><p><strong>6 months to </strong></p><p><strong>12 months </strong></p><p><strong>&nbsp;</strong></p><p><strong>50 mg/kg </strong></p><p><strong>of ceftazidime</strong></p></td><td><p>5</p></td><td><p>250</p></td><td><p>1.5</p></td><td><p>11</p></td></tr><tr><td><p>6</p></td><td><p>300</p></td><td><p>1.8</p></td><td><p>13</p></td></tr><tr><td><p>7</p></td><td><p>350</p></td><td><p>2.1</p></td><td><p>15</p></td></tr><tr><td><p>8</p></td><td><p>400</p></td><td><p>2.4</p></td><td><p>18</p></td></tr><tr><td><p>9</p></td><td><p>450</p></td><td><p>2.7</p></td><td><p>20</p></td></tr><tr><td><p>10</p></td><td><p>500</p></td><td><p>3</p></td><td><p>22</p></td></tr><tr><td><p>11</p></td><td><p>550</p></td><td><p>3.3</p></td><td><p>24</p></td></tr><tr><td><p>12</p></td><td><p>600</p></td><td><p>3.6</p></td><td><p>27</p></td></tr><tr><td rowspan="7"><p><strong>3 months to </strong></p><p><strong>&lt; 6 months </strong></p><p><strong>&nbsp;</strong></p><p><strong>40 mg/kg </strong></p><p><strong>of ceftazidime</strong></p></td><td><p>4</p></td><td><p>160</p></td><td><p>1</p></td><td><p>7.4</p></td></tr><tr><td><p>5</p></td><td><p>200</p></td><td><p>1.2</p></td><td><p>8.8</p></td></tr><tr><td><p>6</p></td><td><p>240</p></td><td><p>1.4</p></td><td><p>10</p></td></tr><tr><td><p>7</p></td><td><p>280</p></td><td><p>1.7</p></td><td><p>13</p></td></tr><tr><td><p>8</p></td><td><p>320</p></td><td><p>1.9</p></td><td><p>14</p></td></tr><tr><td><p>9</p></td><td><p>360</p></td><td><p>2.2</p></td><td><p>16</p></td></tr><tr><td><p>10</p></td><td><p>400</p></td><td><p>2.4</p></td><td><p>18</p></td></tr></tbody></table><p><sup>1 </sup>Based on ceftazidime component only.</p><p>&nbsp;</p><p>Preparation of Zavicefta (final concentration of 20 mg/mL of ceftazidime) in paediatric patients 3 to 12 months of age with CrCL 31 to 50&nbsp;mL/min/1.73 m<sup>2</sup></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td><p><strong>Age and Zavicefta dose (mg/kg)<sup>1</sup></strong></p></td><td><p><strong>Weight (kg)</strong></p></td><td><p><strong>Dose</strong></p><p><strong>(mg ceftazidime)</strong></p></td><td><p><strong>Volume of reconstituted solution to be withdrawn from vial</strong></p><p><strong>(mL)</strong></p></td><td><p><strong>Volume of diluent to add for mixing (mL)</strong></p></td></tr><tr><td rowspan="8"><p><strong>6 months to </strong></p><p><strong>12 months </strong></p><p><strong>&nbsp;</strong></p><p><strong>25 mg/kg </strong></p><p><strong>of ceftazidime</strong></p></td><td><p>5</p></td><td><p>125</p></td><td><p>0.75</p></td><td><p>5.5</p></td></tr><tr><td><p>6</p></td><td><p>150</p></td><td><p>0.9</p></td><td><p>6.6</p></td></tr><tr><td><p>7</p></td><td><p>175</p></td><td><p>1</p></td><td><p>7.4</p></td></tr><tr><td><p>8</p></td><td><p>200</p></td><td><p>1.2</p></td><td><p>8.8</p></td></tr><tr><td><p>9</p></td><td><p>225</p></td><td><p>1.3</p></td><td><p>9.6</p></td></tr><tr><td><p>10</p></td><td><p>250</p></td><td><p>1.5</p></td><td><p>11</p></td></tr><tr><td><p>11</p></td><td><p>275</p></td><td><p>1.6</p></td><td><p>12</p></td></tr><tr><td><p>12</p></td><td><p>300</p></td><td><p>1.8</p></td><td><p>13</p></td></tr><tr><td rowspan="7"><p><strong>3 months to </strong></p><p><strong>&lt; 6 months </strong></p><p><strong>&nbsp;</strong></p><p><strong>20 mg/kg </strong></p><p><strong>of ceftazidime</strong></p></td><td><p>4</p></td><td><p>80</p></td><td><p>0.48</p></td><td><p>3.5</p></td></tr><tr><td><p>5</p></td><td><p>100</p></td><td><p>0.6</p></td><td><p>4.4</p></td></tr><tr><td><p>6</p></td><td><p>120</p></td><td><p>0.72</p></td><td><p>5.3</p></td></tr><tr><td><p>7</p></td><td><p>140</p></td><td><p>0.84</p></td><td><p>6.2</p></td></tr><tr><td><p>8</p></td><td><p>160</p></td><td><p>1</p></td><td><p>7.4</p></td></tr><tr><td><p>9</p></td><td><p>180</p></td><td><p>1.1</p></td><td><p>8.1</p></td></tr><tr><td><p>10</p></td><td><p>200</p></td><td><p>1.2</p></td><td><p>8.8</p></td></tr></tbody></table><p><sup>1 </sup>Based on ceftazidime component only.</p><p>&nbsp;</p><p>Preparation of Zavicefta (final concentration of 20 mg/mL of ceftazidime) in paediatric patients 3 to 12 months of age with CrCL 16 to 30&nbsp;mL/min/1.73 m<sup>2</sup></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td><p><strong>Age and Zavicefta dose (mg/kg)<sup> 1</sup></strong></p></td><td><p><strong>Weight (kg)</strong></p></td><td><p><strong>Dose</strong></p><p><strong>(mg ceftazidime)</strong></p></td><td><p><strong>Volume of reconstituted solution to be withdrawn from vial</strong></p><p><strong>(mL)</strong></p></td><td><p><strong>Volume of diluent to add for mixing (mL)</strong></p></td></tr><tr><td rowspan="8"><p><strong>6 months to </strong></p><p><strong>12 months </strong></p><p><strong>&nbsp;</strong></p><p><strong>18.75 mg/kg </strong></p><p><strong>of ceftazidime</strong></p></td><td><p>5</p></td><td><p>93.75</p></td><td><p>0.56</p></td><td><p>4.1</p></td></tr><tr><td><p>6</p></td><td><p>112.5</p></td><td><p>0.67</p></td><td><p>4.9</p></td></tr><tr><td><p>7</p></td><td><p>131.25</p></td><td><p>0.78</p></td><td><p>5.7</p></td></tr><tr><td><p>8</p></td><td><p>150</p></td><td><p>0.9</p></td><td><p>6.6</p></td></tr><tr><td><p>9</p></td><td><p>168.75</p></td><td><p>1</p></td><td><p>7.4</p></td></tr><tr><td><p>10</p></td><td><p>187.5</p></td><td><p>1.1</p></td><td><p>8.1</p></td></tr><tr><td><p>11</p></td><td><p>206.25</p></td><td><p>1.2</p></td><td><p>8.8</p></td></tr><tr><td><p>12</p></td><td><p>225</p></td><td><p>1.3</p></td><td><p>9.6</p></td></tr><tr><td rowspan="7"><p><strong>3 months to </strong></p><p><strong>&lt; 6 months </strong></p><p><strong>&nbsp;</strong></p><p><strong>15 mg/kg </strong></p><p><strong>of ceftazidime</strong></p></td><td><p>4</p></td><td><p>60</p></td><td><p>0.36</p></td><td><p>2.7</p></td></tr><tr><td><p>5</p></td><td><p>75</p></td><td><p>0.45</p></td><td><p>3.3</p></td></tr><tr><td><p>6</p></td><td><p>90</p></td><td><p>0.54</p></td><td><p>4</p></td></tr><tr><td><p>7</p></td><td><p>105</p></td><td><p>0.63</p></td><td><p>4.6</p></td></tr><tr><td><p>8</p></td><td><p>120</p></td><td><p>0.72</p></td><td><p>5.3</p></td></tr><tr><td><p>9</p></td><td><p>135</p></td><td><p>0.81</p></td><td><p>6</p></td></tr><tr><td><p>10</p></td><td><p>150</p></td><td><p>0.9</p></td><td><p>6.6</p></td></tr></tbody></table><p><sup>1 </sup>Based on ceftazidime component only.</p><p>&nbsp;</p><p><u>Paediatric patients from birth (including preterm) to &lt; 3 months of age:</u></p><p><u>&nbsp;</u></p><p>NOTE: The following procedure describes the steps to prepare a stock infusion solution with a final concentration of 10 mg/mL of ceftazidime appropriate for administering doses under 250 mg to paediatric patients from birth (including preterm) to &lt; 3 months of age. Alternative concentrations may be prepared, but must have a final concentration range of 8-40 mg/mL of ceftazidime.</p><p>&nbsp;</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp; Prepare the <strong>reconstituted solution (167.3 mg/mL</strong> of ceftazidime):</p><p>a)&nbsp;&nbsp;&nbsp;&nbsp; Insert the syringe needle through the vial closure and inject 10 mL of sterile water for injections.</p><p>b)&nbsp;&nbsp;&nbsp;&nbsp; Withdraw the needle and shake the vial to give a clear solution.</p><p>c)&nbsp;&nbsp;&nbsp;&nbsp; Insert a gas relief needle through the vial closure <strong>after</strong> the product has dissolved to relieve the internal pressure (this is important to preserve product sterility).</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp; Prepare the <strong>final stock solution</strong> for infusion to a final concentration of <strong>10 mg/mL</strong> of ceftazidime:</p><p>a)&nbsp;&nbsp;&nbsp;&nbsp; Further dilute the reconstituted solution by transferring 3 mL of the reconstituted solution to an infusion bag or a syringe containing 47 mL of diluent (sodium chloride 9 mg/mL (0.9%) solution for injection or dextrose 50 mg/mL (5%) solution for injection) to provide a final volume of 50 mL.</p><p>b)&nbsp;&nbsp;&nbsp;&nbsp; Mix thoroughly (e.g. gently invert the infusion bag or using a syringe connector gently pass the solution back and forth at least 5 times between 2 syringes).</p><p>c)&nbsp;&nbsp;&nbsp;&nbsp; Transfer an appropriate volume of the <strong>10 mg/mL</strong> of ceftazidime stock solution to an infusion syringe. Refer to the table below for the volume of the stock solution to transfer to the infusion syringe to be administered. Values shown are approximate as it may be necessary to round to the nearest graduation mark of an appropriately sized syringe.</p><p>Note that the tables are NOT inclusive of all possible calculated doses but may be utilised to estimate the approximate volume to verify the calculation.</p><p>&nbsp;</p><p>Zavicefta dosing in paediatric patients from birth (including preterm) to &lt; 3 months of age using a 50&nbsp;mL stock solution of Zavicefta (final concentration of 10 mg/mL of ceftazidime) prepared with 3&nbsp;mL reconstituted solution withdrawn from the vial and added to 47 mL diluent.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td><p><strong>Age and Zavicefta dose (mg/kg)<sup>1</sup></strong></p></td><td><p><strong>Weight (kg)</strong></p></td><td><p><strong>Dose </strong></p><p><strong>(mg ceftazidime)</strong></p></td><td><p><strong>Volume of 10 mg/mL (ceftazidime) stock solution to be administered (mL)</strong></p></td></tr><tr><td rowspan="11"><p>Full term infants (gestation &ge;&nbsp;37&nbsp;weeks) from &gt;&nbsp;28&nbsp;days to &lt;&nbsp;3&nbsp;months</p><p>&nbsp;</p><p>OR</p><p>&nbsp;</p><p>Preterm infants from &gt;&nbsp;44&nbsp;weeks to &lt; 53 weeks PMA</p><p>&nbsp;</p><p><strong>30 mg/kg of ceftazidime</strong></p></td><td><p>3</p></td><td><p>90</p></td><td><p>9</p></td></tr><tr><td><p>3.5</p></td><td><p>105</p></td><td><p>10.5</p></td></tr><tr><td><p>4</p></td><td><p>120</p></td><td><p>12</p></td></tr><tr><td><p>4.5</p></td><td><p>135</p></td><td><p>13.5</p></td></tr><tr><td><p>5</p></td><td><p>150</p></td><td><p>15</p></td></tr><tr><td><p>5.5</p></td><td><p>165</p></td><td><p>16.5</p></td></tr><tr><td><p>6</p></td><td><p>180</p></td><td><p>18</p></td></tr><tr><td><p>6.5</p></td><td><p>195</p></td><td><p>19.5</p></td></tr><tr><td><p>7</p></td><td><p>210</p></td><td><p>21</p></td></tr><tr><td><p>7.5</p></td><td><p>225</p></td><td><p>22.5</p></td></tr><tr><td><p>8</p></td><td><p>240</p></td><td><p>24</p></td></tr><tr><td rowspan="18"><p>Full term neonates (gestation &ge;&nbsp;37&nbsp;weeks) from birth to &le;&nbsp;28&nbsp;days</p><p>&nbsp;</p><p>OR</p><p>&nbsp;</p><p>Preterm neonates and infants from 26 to &le;&nbsp;44&nbsp;weeks PMA</p><p>&nbsp;</p><p><strong>20 mg/kg of ceftazidime</strong></p></td><td><p>0.8</p></td><td><p>16</p></td><td><p>1.6</p></td></tr><tr><td><p>1</p></td><td><p>20</p></td><td><p>2</p></td></tr><tr><td><p>1.2</p></td><td><p>24</p></td><td><p>2.4</p></td></tr><tr><td><p>1.4</p></td><td><p>28</p></td><td><p>2.8</p></td></tr><tr><td><p>1.6</p></td><td><p>32</p></td><td><p>3.2</p></td></tr><tr><td><p>1.8</p></td><td><p>36</p></td><td><p>3.6</p></td></tr><tr><td><p>2</p></td><td><p>40</p></td><td><p>4</p></td></tr><tr><td><p>2.2</p></td><td><p>44</p></td><td><p>4.4</p></td></tr><tr><td><p>2.4</p></td><td><p>48</p></td><td><p>4.8</p></td></tr><tr><td><p>2.6</p></td><td><p>52</p></td><td><p>5.2</p></td></tr><tr><td><p>2.8</p></td><td><p>56</p></td><td><p>5.6</p></td></tr><tr><td><p>3</p></td><td><p>60</p></td><td><p>6</p></td></tr><tr><td><p>3.5</p></td><td><p>70</p></td><td><p>7</p></td></tr><tr><td><p>4</p></td><td><p>80</p></td><td><p>8</p></td></tr><tr><td><p>4.5</p></td><td><p>90</p></td><td><p>9</p></td></tr><tr><td><p>5</p></td><td><p>100</p></td><td><p>10</p></td></tr><tr><td><p>5.5</p></td><td><p>110</p></td><td><p>11</p></td></tr><tr><td><p>6</p></td><td><p>120</p></td><td><p>12</p></td></tr></tbody></table><p><sup>1&nbsp;</sup>Based on ceftazidime component only.</p><p>&nbsp;</p><p>Store in the original package in order to protect from light.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer require. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substances are ceftazidime and avibactam. Each vial contains ceftazidime pentahydrate equivalent to 2&nbsp;g ceftazidime and avibactam sodium equivalent to 0.5&nbsp;g avibactam.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredient is sodium carbonate (anhydrous) (see section 2 &ldquo;Zavicefta contains sodium&rdquo;).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	Zavicefta is a white to pale yellow powder for concentrate for solution for infusion in a vial. It is available in packs containing 10 vials.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder </strong></p><p>Pfizer Ireland Pharmaceuticals</p><p>Ireland</p><p>&nbsp;</p><p>Manufacturer</p><p>ACS Dobfar S.p.A.</p><p>Italy</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                October 2024
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>ما هو زافيسيفتا</strong></p><p dir="RTL">زافيسيفتا هو مضاد حيوي يحتوي على مادتين فعالتين هما سيفتازيديم وأفيباكتام.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينتمي سيفتازيديم إلى مجموعة من المضادات الحيوية تُدعى &quot;السيفالوسبورينات&quot;، ويمكنه القضاء على الكثير من أنواع البكتيريا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أفيباكتام هو &quot;مثبط للبيتا-لاكتاماز&quot; يساعد سيفتازيديم بالقضاء على بعض أنواع البكتيريا التي لا يمكنه القضاء عليها بمفرده.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>وما هي دواعي استعماله </strong></p><p dir="RTL">يُستخدم زافيسيفتا في البالغين والمرضى من الأطفال في سن الولادة لعلاج:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى المعدة والأحشاء (البطن)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى المثانة أو الكلى وتدعى &quot;عدوى المسالك البولية&quot;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى بالرئتين تدعى &quot;الالتهاب الرئوي&quot;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالات العدوى التي تسببها بكتيريا لا يمكن للمضادات الحيوية الأخرى القضاء عليها</p><p dir="RTL">يُستخدم زافيسيفتا في البالغين لعلاج عدوى الدم المرتبطة بعدوى البطن، أو المسالك البولية، أو الالتهاب الرئوي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>طريقة عمل زافيسيفتا</strong></p><p dir="RTL">يعمل زافيسيفتا عن طريق القضاء على أنواع معينة من البكتيريا التي يمكنها أن تسبب حالات عدوى خطيرة.</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <table dir="rtl" border="1" cellspacing="0" cellpadding="0" align="right" style="width:100%"><tbody><tr><td style="vertical-align:bottom"><p dir="RTL"><strong>موانع استعمال زافيسيفتا: </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بالحساسية تجاه سيفتازيديم أو أفيباكتام أو تجاه أي مكون آخر من مكونات هذا الدواء (المدرجة في القسم ٦)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بالحساسية تجاه المضادات الحيوية الأخرى من فئة السيفالوسبورينات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد سبقت لك الإصابة بتفاعل حساسية شديد تجاه مضادات حيوية أخرى تنتمي لفئة البنسلينات أو الكاربابينيمات</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم زافيسيفتا إذا انطبقت أي من الحالات الواردة أعلاه عليك. إذا لم تكن متأكدًا، فتحدث إلى طبيبك أو الممرضة قبل استخدام زافيسيفتا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاحتياطات عند استعمال زافيسيفتا</strong></p><p dir="RTL">تحدث إلى طبيبك أو الممرضة قبل استخدام زافيسيفتا إذا كنت:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد سبقت لك الإصابة بأي تفاعل حساسية (حتى ولو كان مجرد طفح جلدي) تجاه مضادات حيوية أخرى تنتمي لفئة البنسلينات أو الكاربابينيمات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعاني من مشكلات بالكليتين - يمكن أن يعطيك طبيبك جرعة أقل لضمان عدم تلقيك لكمية من الدواء أكبر مما ينبغي. يمكن أن يسبب هذا أعراضًا مثل النوبات (انظر القسم &quot;<strong>إذا استخدمت زافيسيفتا بكمية أكبر مما ينبغي</strong>&quot;)</p><p dir="RTL">إذا انطبقت عليك أي من الحالات الواردة أعلاه (أو إذا لم تكن متأكدًا)، فتحدث إلى طبيبك أو الممرضة قبل استخدام زافيسيفتا. تحدث إلى طبيبك أو الممرضة إذا أصبت بالإسهال أثناء علاجك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>حالات العدوى الأخرى</u></p><p dir="RTL">هناك احتمال صغير بأنك قد تصاب بعدوى مختلفة تسببها بكتيريا أخرى أثناء العلاج بزافيسيفتا أو بعده. يشمل هذا القلاع (عدوى فطرية بالفم أو منطقة الأعضاء التناسلية).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الاختبارات المعملية</u></p><p dir="RTL">أخبر طبيبك بأنك تتناول زافيسيفتا إذا كنت ستخضع لأي اختبارات، نظرًا لاحتمال ظهور نتيجة غير طبيعية لاختبار يدعى &quot;الاختبار المباشر للأجسام المضادة للجلوبيولين البشري (DAGT)&quot; أو &quot;كومبس&quot;. يبحث هذا الاختبار عن الأجسام المضادة التي تهاجم خلايا دمك الحمراء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أن يؤثر زافيسيفتا أيضًا على نتائج بعض اختبارات السكر التي يتم إجراؤها على البول. أخبر الشخص الذي يأخذ العينة بأنك قد تلقيت زافيسيفتا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التداخلات الدوائية م</strong><strong>ع</strong><strong> أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">أخبر طبيبك أو الممرضة إذا كنت تستخدم أو استخدمت مؤخرًا أو قد تستخدم أي أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحدث إلى طبيبك قبل استخدام زافيسيفتا إذا كنت تتناول أيًا من الأدوية التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادًا حيويًا يُدعى كلورامفينيكول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوعًا من المضادات الحيوية يطلق عليه أمينوجليكوزيد - مثل جنتامايسين، توبرامايسين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قرص مدر للبول يدعى فوروسيميد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دواءً لعلاج النقرس يُدعى بروبينيسيد</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك قبل استخدام زافيسيفتا إذا انطبقت أي من الحالات الواردة أعلاه عليك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">إذا كنتِ حاملًا أو ترضعين رضاعة طبيعية، أو تعتقدين أنك ربما تكونين حاملًا أو تخططين للحمل، فاستشيري طبيبك قبل استخدام هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثير زافيسيفتا على القيادة واستخدام الآلات</strong></p><p dir="RTL">قد يجعلك زافيسيفتا تشعر بالدوار. يمكن أن يؤثر هذا على قدرتك على القيادة أو استخدام الأدوات أو الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>معلومات</strong> <strong>هامة حول بعض مكونات زافيسيفتا</strong></p><p dir="RTL"><strong>يحتوي زافيسيفتا على الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على الصوديوم&nbsp; (مكون أساسي لملح الطعام/المائدة).</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي إذا كنت بحاجة إلى ٣ قوارير أو أكثر يوميًا لفترة مطولة، خاصة إذا كان قد تم نُصحك باتباع نظام غذائي منخفض الملح (الصوديوم).</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL">سيتم إعطاؤك زافيسيفتا بواسطة طبيب أو ممرض/ممرضة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الكمية التي ينبغي استخدامها</strong></p><p dir="RTL">الجرعة الموصى بها للبالغين هي قارورة واحدة (٢ جرام سيفتازيديم و٠,٥ جرام أفيباكتام)، كل ٨ ساعات. سيتم حساب جرعة المرضى من الأطفال في سن الولادة من قِبَل الطبيب بناءً على وزن وعمر الطفل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتم إعطاء هذه الجرعة بالتنقيط في أحد الأوردة &ndash; سوف يستغرق هذا عادةً حوالي ساعتين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تستغرق دورة العلاج عادة من ٥ أيام لما يصل إلى ١٤ يومًا، على حسب نوع العدوى التي تعاني منها وكيفية استجابتك للعلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الأشخاص الذين يعانون من مشكلات بالكلى</u></p><p dir="RTL">إذا كانت لديك مشكلات بالكليتين، فقد يعطيك طبيبك جرعة أقل، وهذا لأن زافيسيفتا يتم إخراجه من جسمك بواسطة الكليتين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة الزائدة من زافيسيفتا</strong></p><p dir="RTL">سيتم إعطاؤك زافيسيفتا بواسطة طبيب أو ممرضة، لذلك فمن غير المرجح أن يتم إعطاؤك جرعة خاطئة. ولكن، إذا تعرضت لأي أعراض جانبية، أو إذا كنت تعتقد بأنك قد أُعطيت جرعة من زافيسيفتا أكبر مما ينبغي، فأخبر طبيبك أو الممرضة على الفور. إذا استخدمت زافيسيفتا بكمية أكبر مما ينبغي، فقد يؤثر على الدماغ ويسبب النوبات أو الغيبوبة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نسيان تناول جرعة زافيسيفتا</strong></p><p dir="RTL">إذا كنت تعتقد أنه قد فاتك تلقي إحدى الجرعات، فأخبر طبيبك أو الممرضة على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أي أسئلة أخرى حول استخدام هذا الدواء، فاسأل طبيبك أو الممرضة.</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <table dir="rtl" border="1" cellspacing="0" cellpadding="0" align="right" style="width:100%"><tbody><tr><td style="vertical-align:bottom"><p dir="RTL">كما هو الحال بالنسبة لجميع الأدوية، من الممكن أن يسبب هذا الدواء أعراضًا جانبية، إلا أنها لا تصيب الجميع. قد تحدث الأعراض الجانبية التالية عند استخدام هذا الدواء:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية الخطيرة</strong></p><p dir="RTL">أخبر طبيبك على الفور إذا لاحظت أيًا من الأعراض الجانبية الخطيرة التالية - قد تحتاج إلى علاج طبي عاجل:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية شديدة - تشمل العلامات تورمًا مفاجئًا لشفتيك أو وجهك أو حلقك أو لسانك، طفحًا جلديًا شديدًا أو تفاعلات جلدية شديدة أخرى، صعوبة في البلع أو التنفس، أو ألم مفاجئ في الصدر (الذي قد يكون علامة على الإصابة بمتلازمة كونيس). قد تكون هذه التفاعلات مهددةً للحياة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال الذي تصبح حالته أسوأ أو لا يزول، أو البراز الذي يحتوي على دم أو مخاط - يمكن أن يحدث هذا أثناء العلاج بزافيسيفتا أو بعد إيقافه. في حالة حدوث هذا، لا تتناول أي أدوية تعمل على إيقاف أو إبطاء حركة الأمعاء.</p><p dir="RTL">أخبر طبيبك على الفور إذا لاحظت أيًا من الأعراض الجانبية الخطيرة الواردة أعلاه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية الأخرى</strong></p><p dir="RTL">أخبر طبيبك أو الممرضة إذا لاحظت أيًا من الأعراض الجانبية التالية:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة جدًا: </strong>(قد تصيب أكثر من شخص واحد من بين كل ١٠ أشخاص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نتيجة غير طبيعية لاختبار يدعى &quot;الاختبار المباشر للأجسام المضادة للجلوبيولين البشري&quot; أو &quot;كومبس&quot;. يبحث هذا الاختبار عن الأجسام المضادة التي تهاجم خلايا دمك الحمراء. يمكن أن يسبب هذا فقر الدم (الذي قد يجعلك تشعر بالتعب) واليرقان (اصفرار الجلد والعينين)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة: </strong>(قد تصيب ما يصل إلى شخص واحد من بين كل ١٠ أشخاص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى الفطرية، بما في ذلك العدوى الفطرية بالفم والمهبل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير في عدد بعض أنواع خلايا الدم (تدعى &quot;اليوزينيات&quot; و&quot;الصفيحات&quot;) - يظهر في فحوصات الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالدوار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالرغبة في التقيؤ (الغثيان) أو القيء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم المعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في كمية بعض الإنزيمات التي ينتجها كبدك - تظهر في فحوصات الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي بارز مصحوب بحكة (&quot;الشرى&quot;)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحكة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار أو ألم أو تورم في موضع إعطاء زافيسيفتا في الوريد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة: </strong>(قد تصيب ما يصل إلى شخص واحد من بين كل ١٠٠ شخص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في عدد بعض أنواع خلايا الدم (تدعى &quot;الليمفاويات&quot;) - تظهر في فحوصات الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في عدد بعض أنواع خلايا الدم (تدعى &quot;الكريات البيضاء&quot;) - يظهر في فحوصات الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التنميل أو الخدر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بمذاق سيء في فمك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في مستويات بعض أنواع المواد في دمك (تدعى &quot;الكرياتينين&quot; و&quot;اليوريا&quot;). تًظهر هذه المستويات مدى الكفاءة التي تعمل بها كليتاك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة جدًا: </strong>(قد تصيب ما يصل إلى شخص واحد من بين كل ١٠٠٠٠ شخص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم في جزء من الكلية يسبب انخفاضًا في أدائه الوظيفي الطبيعي</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير معروف</strong>: (لا يمكن تقدير معدل التكرار من البيانات المتاحة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض كبير في نوع من خلايا الدم البيضاء يستخدمها الجسم لمحاربة العدوى - يظهر في فحوصات الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في عدد خلايا الدم الحمراء (فقر الدم الانحلالي) - يظهر في فحوصات الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل حساسية شديد (انظر قسم <strong>&quot;الأعراض الجانبية الخطيرة&quot; </strong>أعلاه)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار بياض العينين أو الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بدء مفاجئ لطفح جلدي شديد أو تبثر أو تقشر جلدي شديد، قد يكون مصحوبًا بحمى شديدة أو ألم بالمفاصل (قد تكون هذه علامات لحالة طبية أكثر خطورة مثل تقشر الأنسجة المتموتة البشروية التسممي، أو متلازمة ستيفنز-جونسون، أو الاحمرار الجلدي عديد الأشكال أو حالة تعرف بالتفاعلات الدوائية المصحوبة بكثرة اليوزينات وأعراض جهازية (DRESS))</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم تحت الجلد، خاصة الشفتين وحول العينين</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك أو الممرضة إذا لاحظت أيًا من الأعراض الجانبية المدرجة أعلاه.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية:</strong></p><p dir="RTL">إذا أصبت بأي آثار جانبية، فتحدث إلى طبيبك أو الممرض/الممرضة. يشمل هذا أي آثار جانبية محتملة غير مدرجة في هذه النشرة. بالإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول السلامة فيما يتعلق بهذا الدواء.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>للإبلاغ عن أي عرض جانبي </strong><strong>&nbsp;(أعراض جانبية)</strong><strong>:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المملكة العربية السعودية</strong></p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">المركز الوطني للتيقظ الدوائي</p><p dir="RTL"><strong><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong>مركز الاتصال الموحد: ١٩٩٩٩</p><p dir="RTL"><strong><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong>البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>الموقع الإلكتروني: https://ade.sfda.gov.sa</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>دول الخليج الأخرى</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><em>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em><em>الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.</em></p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <table dir="rtl" border="1" cellspacing="0" cellpadding="0" align="right" style="width:100%"><tbody><tr><td style="vertical-align:bottom"><p dir="RTL">يحفظ في درجة حرارة أقل من ٣٠ درجة مئوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">احتفظ بهذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد مرور تاريخ انتهاء الصلاحية المُبين على الحاوية. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في الشهر المذكور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>مدة صلاحية المسحوق الجاف:</u> ٣ سنوات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>مدة الصلاحية بعد التحضير:</u> ينبغي أن تُستخدم القارورة المُحضرة على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>مدة الصلاحية بعد التخفيف</u></p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>أكياس التسريب</em></p><p dir="RTL">إذا تم تحضير المحلول الوريدي بالمواد المخففة الواردة في القسم ٦.٦ (تركيز سيفتازيديم ٨ ملجم/مل)، فقد ثبت الاستقرار الكيميائي والفيزيائي للمحلول الجاهز للاستخدام (منذ الثقب الأولي للقارورة) لمدة تصل إلى ١٢ ساعة في درجة حرارة تتراوح بين درجتين و٨ درجات مئوية، يتبعها مدة تصل إلى ٤ ساعات في درجة حرارة لا تتجاوز ٢٥ درجة مئوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا تم تحضير المحلول الوريدي بالمواد المخففة الواردة في القسم ٦.٦ (تركيز سيفتازيديم أكبر من ٨ ملجم/مل إلى ٤٠ ملجم/مل)، فقد ثبت الاستقرار الكيميائي والفيزيائي للمحلول الجاهز للاستخدام (منذ الثقب الأولي للقارورة) لمدة تصل إلى ٤ ساعات في درجة حرارة لا تتجاوز ٢٥ درجة مئوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">من وجهة نظر ميكروبيولوجية، ينبغي استخدام المستحضر الدوائي على الفور ما لم يتم التحضير والتخفيف في ظروف تعقيم مُراقبة وتم التحقق منها. وإذا لم يُستخدم فورًا، فإن مسؤولية الالتزام بمدد وظروف التخزين للمحلول الجاهز للاستخدام قبل استخدامه تقع على عاتق المستخدم، ويجب ألا تتجاوز المدد المذكورة أعلاه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>محاقن التسريب</em></p><p dir="RTL">إذا تم تحضير المحلول الوريدي بالمواد المخففة الواردة في القسم ٦.٦ (تركيز سيفتازيديم يُعادل ٨ ملجم/مل إلى ٤٠ ملجم/مل أو أكثر)، فقد ثبت الاستقرار الكيميائي والفيزيائي للمحلول الجاهز للاستخدام (منذ الثقب الأولي للقارورة) لمدة تصل إلى ٦ ساعات في درجة حرارة لا تتجاوز ٢٥ درجة مئوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">من وجهة نظر ميكروبيولوجية، ينبغي استخدام المستحضر الدوائي على الفور، ما لم يتم التحضير والتخفيف في ظروف تعقيم مُراقبة وتم التحقق منها. وإذا لم يُستخدم فورًا، فإن مسؤولية الالتزام بمدد وظروف التخزين للمحلول الجاهز للاستخدام قبل استخدامه تقع على عاتق المستخدم، ويجب ألا تزيد عن ٦ ساعات في درجة حرارة لا تتجاوز ٢٥ درجة مئوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">زافيسيفتا (سيفتازيديم/أفيباكتام) هو منتج مركب؛ تحتوي كل قارورة على ٢ جم من سيفتازيديم و٠٫٥ جم من أفيباكتام بنسبة ثابتة ١:٤. تعتمد توصيات الجرعة على مكون سيفتازيديم فقط.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي استخدام تقنيات التعقيم القياسية لتحضير المحلول واستعماله. يمكن تحضير الجرعات في كيس تسريب أو محقنة تسريب بحجم مناسب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي إعطاء المحلول الناتج على مدار ١٢٠ دقيقة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">كل قارورة مخصصة للاستخدام مرة واحدة فقط.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي التخلص من أي منتج غير مستخدم أو نفايات وفقًا للمتطلبات المحلية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي ألا يتجاوز إجمالي الفترة الفاصلة بين بدء التحضير وإكمال تجهيز محلول التسريب الوريدي مدة ٣٠ دقيقة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>تعليمات تحضير جرعات البالغين والأطفال في كيس التسريب أو محقنة التسريب:</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">ملاحظة: يصف الإجراء التالي خطوات تحضير محلول للتسريب ذي تركيز نهائي قدره ٨-٤٠ ملجم/مل من سيفتازيديم. ينبغي إكمال جميع الحسابات قبل بدء هذه الخطوات.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>للمرضى من الأطفال الذين تتراوح أعمارهم بين ٣ أشهر و١٢ شهرًا،</strong> ترد أدناه خطوات مفصلة لتحضير محلول تركيزه ٢٠ ملجم/مل (مناسب لمعظم الحالات).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>للمرضى من الأطفال في سن الولادة (بما في ذلك الأطفال الخدج) وحتى عمر أقل من ٣ أشهر،</strong> ترد أدناه خطوات مفصلة لتحضير <strong>محلول تركيزه ١٠ ملجم/مل</strong> (مناسب لمعظم الحالات).</p><p dir="RTL">&nbsp;</p><p dir="RTL">١.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جهز <strong>المحلول المُحضَّر</strong> (<strong>١٦٧٫٣ ملجم/مل</strong> من سيفتازيديم):</p><p dir="RTL">أ)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدخل إبرة المحقنة عبر غطاء القارورة واحقن ١٠ مل من الماء المعقم المخصص للحقن.</p><p dir="RTL">ب)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اسحب الإبرة ورج القارورة لينتج محلول صاف.</p><p dir="RTL">ج)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدخل إبرة تفريغ غاز عبر غطاء القارورة <strong>بعد</strong> ذوبان المنتج لتخفيف الضغط الداخلي (هذه خطوة مهمة للحفاظ على تعقيم المنتج).</p><p dir="RTL">٢.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جهز <strong>المحلول النهائي</strong> المخصص للتسريب (يجب أن يبلغ التركيز النهائي <strong>٨-٤٠ ملجم/مل </strong>من سيفتازيديم):</p><p dir="RTL">أ)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كيس التسريب: عليك زيادة معدل تخفيف المحلول المُحضَّر عن طريق نقل حجم محسوب بدقة منه إلى كيس تسريب يحتوي على أي من التالي: محلول كلوريد الصوديوم &rlm;٩&rlm; ملجم/مل (&rlm;٠٫٩&rlm; ٪) المخصص للحقن أو محلول ديكستروز &rlm;٥٠&rlm; ملجم/مل (&rlm;٥&rlm; ٪) المخصص للحقن أو محلول لاكتات رينجر.</p><p dir="RTL">ب)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; محقنة التسريب: عليك زيادة معدل تخفيف المحلول المُحضَّر عن طريق نقل حجم محسوب بدقة منه ممزوجًا بحجم كافٍ من المادة المخففة (محلول كلوريد الصوديوم ٩&rlm; ملجم/مل (&rlm;٠٫٩&rlm; ٪) المخصص للحقن أو محلول ديكستروز &rlm;٥٠&rlm; ملجم/مل (&rlm;٥&rlm; ٪) المخصص للحقن) إلى محقنة تسريب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">راجع الجدول أدناه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحضير جرعات زافيسيفتا للبالغين والأطفال في كيس تسريب أو محقنة تسريب.</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>جرعة زافيسيفتا</strong></p><p dir="RTL"><strong>(سيفتازيديم)</strong><sup>١</sup></p></td><td style="vertical-align:top"><p dir="RTL"><strong>الحجم المسحوب من قارورة المحلول المُحضَّر</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>الحجم النهائي بعد التخفيف في كيس التسريب<sup>٢</sup></strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>الحجم النهائي في محقنة التسريب<sup>٣</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">٢ جم</p></td><td><p dir="RTL">المحتويات كلها (١٢ مل تقريبًا)</p></td><td><p dir="RTL">٥٠ مل إلى ٢٥٠ مل</p></td><td><p dir="RTL">٥٠ مل</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">١ جم</p></td><td><p dir="RTL">٦ مل</p></td><td><p dir="RTL">٢٥ مل إلى ١٢٥ مل</p></td><td><p dir="RTL">٢٥ مل إلى ٥٠ مل</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">٠٫٧٥ جم</p></td><td><p dir="RTL">٤٫٥ مل</p></td><td><p dir="RTL">١٩ مل إلى ٩٣ مل</p></td><td><p dir="RTL">١٩ مل إلى ٥٠ مل</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">جميع الجرعات الأخرى</p></td><td><p dir="RTL">الحجم (مل) محسوبًا بناءً على الجرعة المطلوبة:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة (ملجم سيفتازيديم) &divide; ١٦٧٫٣ ملجم/مل سيفتازيديم</strong></p><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">سيختلف الحجم (مل) بناءً على حجم كيس التسريب المتوفر والتركيز النهائي المُفضَّل.</p><p dir="RTL">(يجب أن يكون ٨-٤٠ ملجم/مل من سيفتازيديم)</p></td><td><p dir="RTL">سيختلف الحجم (مل) بناءً على حجم محقنة التسريب المتوفر والتركيز النهائي المُفضَّل.</p><p dir="RTL">(يجب أن يكون ٨-٤٠ ملجم/مل من سيفتازيديم)</p></td></tr></tbody></table><p dir="RTL"><sup>١ </sup>بناءً على مكون سيفتازيديم فقط.</p><p dir="RTL"><sup>٢</sup> قم بالتخفيف للحصول على تركيز نهائي من سيفتازيديم يبلغ ٨ ملجم/مل، بهذا ستصل مدة استقرار المحلول الجاهز للاستخدام إلى ١٢ ساعة في درجة حرارة ٢-٨ درجات مئوية، تليها مدة استقرار تصل إلى ٤ ساعات في درجة حرارة لا تتجاوز ٢٥ درجة مئوية (أي خفف جرعة ٢ جم من سيفتازيديم في ٢٥٠ مل، جرعة ١ جم من سيفتازيديم في ١٢٥ مل، جرعة ٠٫٧٥ جم من سيفتازيديم في ٩٣ مل، إلخ.). أما جميع تركيزات سيفتازيديم الأخرى (الأكبر من&nbsp;٨&nbsp;ملجم/مل إلى ٤٠&nbsp;ملجم/مل)، فيستمر استقرار المحلول الجاهز للاستخدام لمدة تصل إلى ٤&nbsp;ساعات في درجة حرارة لا تتجاوز ٢٥ درجة مئوية.</p><p dir="RTL"><sup>٣</sup> قم بالتخفيف للحصول على تركيز نهائي من سيفتازيديم يُعادل ٨&nbsp;ملجم/مل إلى ٤٠&nbsp;ملجم/مل أو أكثر، بهذا ستصل مدة استقرار المحلول الجاهز للاستخدام إلى ٦&nbsp;ساعات في درجة حرارة لا تتجاوز ٢٥ درجة مئوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>المرضى من الأطفال الذين تتراوح أعمارهم بين ٣ أشهر و١٢ شهرًا</u></p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL">ملاحظة: يصف الإجراء التالي خطوات تحضير محلول للتسريب ذي تركيز نهائي قدره ٢٠ ملجم/مل من سيفتازيديم (مناسب لمعظم الحالات). ويمكن إعداد تركيزات بديلة، لكن يجب أن يبلغ التركيز النهائي من سيفتازيديم &rlm;٨&rlm;-&rlm;٤٠&rlm; ملجم/مل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">١.<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>جهز <strong>المحلول المُحضَّر</strong> (<strong>١٦٧٫٣ ملجم/مل</strong> من سيفتازيديم):</p><p dir="RTL">أ&zwnj;)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدخل إبرة المحقنة عبر غطاء القارورة واحقن ١٠&nbsp;مل من الماء المعقم المخصص للحقن.</p><p dir="RTL">ب&zwnj;)&nbsp;&nbsp;&nbsp; اسحب الإبرة ورج القارورة لينتج محلول صاف.</p><p dir="RTL">ج&zwnj;)&nbsp;&nbsp;&nbsp; أدخل إبرة تفريغ غاز عبر غطاء القارورة <strong>بعد</strong> ذوبان المنتج لتخفيف الضغط الداخلي (هذه خطوة مهمة للحفاظ على تعقيم المنتج).</p><p dir="RTL">٢.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جهز <strong>المحلول النهائي</strong> المخصص للتسريب بتركيز نهائي يبلغ <strong>٢٠ ملجم/مل</strong> من سيفتازيديم:</p><p dir="RTL">أ&zwnj;)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عليك زيادة معدل تخفيف المحلول المُحضَّر عن طريق نقل حجم محسوب بدقة منه ممزوجًا بحجم كافٍ من المادة المخففة (محلول كلوريد الصوديوم ٩&rlm; ملجم/مل (&rlm;٠٫٩&rlm; ٪) المخصص للحقن أو محلول ديكستروز &rlm;٥٠&rlm; ملجم/مل (&rlm;٥&rlm; ٪) المخصص للحقن) إلى محقنة تسريب.</p><p dir="RTL">ب&zwnj;)&nbsp;&nbsp;&nbsp; ارجع إلى الجداول الواردة أدناه للتأكد من الحسابات. مع العلم أن القيم الموضحة تقريبية، فقد يكون من الضروري التقريب إلى أقرب علامة تدريج موضحة على إحدى المحاقن ذات الحجم المناسب. يرجى ملاحظة أن الجداول لا تشمل جميع الجرعات المحسوبة المحتملة، ولكن يمكن استخدامها لتقدير الحجم التقريبي بهدف التأكد من صحة من الحسابات.</p><p dir="RTL">تحضير جرعات زافيسيفتا (تركيز نهائي ٢٠ ملجم/مل من سيفتازيديم) للمرضى من الأطفال الذين تتراوح أعمارهم بين ٣ أشهر و١٢&nbsp;شهرًا ممن يزيد معدل تصفية الكرياتينين (CrCL) لديهم عن ٥٠ مل/دقيقة/١٫٧٣ م<sup>٢</sup></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><thead><tr><td><p dir="RTL"><strong>العمر وجرعة زافيسيفتا (ملجم/كلجم)<sup>١</sup></strong></p></td><td><p dir="RTL"><strong>الوزن (كلجم)</strong></p></td><td><p dir="RTL"><strong>الجرعة</strong></p><p dir="RTL"><strong>(ملجم سيفتازيديم)</strong></p></td><td><p dir="RTL"><strong>حجم المحلول المُحضَّر المسحوب من القارورة</strong></p><p dir="RTL"><strong>(مل)</strong></p></td><td><p dir="RTL"><strong>حجم المادة المخففة المضاف من أجل المزج (مل)</strong></p></td></tr></thead><tbody><tr><td rowspan="8"><p dir="RTL"><strong>من ٦ أشهر إلى</strong></p><p dir="RTL"><strong>١٢ شهرًا</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>٥٠ ملجم/كلجم</strong></p><p dir="RTL"><strong>من سيفتازيديم</strong></p></td><td><p dir="RTL">&rlm;٥&rlm;</p></td><td><p dir="RTL">٢٥٠</p></td><td><p dir="RTL">١٫٥</p></td><td><p dir="RTL">١١</p></td></tr><tr><td><p dir="RTL">٦</p></td><td><p dir="RTL">۳۰۰</p></td><td><p dir="RTL">١٫٨</p></td><td><p dir="RTL">۱۳</p></td></tr><tr><td><p dir="RTL">۷</p></td><td><p dir="RTL">۳٥۰</p></td><td><p dir="RTL">٢٫١</p></td><td><p dir="RTL">۱٥</p></td></tr><tr><td><p dir="RTL">۸</p></td><td><p dir="RTL">٤۰۰</p></td><td><p dir="RTL">٢٫٤</p></td><td><p dir="RTL">۱۸</p></td></tr><tr><td><p dir="RTL">۹</p></td><td><p dir="RTL">٤٥۰</p></td><td><p dir="RTL">٢٫٧</p></td><td><p dir="RTL">۲۰</p></td></tr><tr><td><p dir="RTL">۱۰</p></td><td><p dir="RTL">٥۰۰</p></td><td><p dir="RTL">۳</p></td><td><p dir="RTL">۲۲</p></td></tr><tr><td><p dir="RTL">۱۱</p></td><td><p dir="RTL">٥٥۰</p></td><td><p dir="RTL">٣٫٣</p></td><td><p dir="RTL">۲٤</p></td></tr><tr><td><p dir="RTL">۱۲</p></td><td><p dir="RTL">٦۰۰</p></td><td><p dir="RTL">٣٫٦</p></td><td><p dir="RTL">۲۷</p></td></tr><tr><td rowspan="7"><p dir="RTL"><strong>من </strong><strong>۳</strong><strong> أشهر إلى</strong></p><p dir="RTL"><strong>أقل من ٦ أشهر</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>٤٠ ملجم/كلجم</strong></p><p dir="RTL"><strong>من سيفتازيديم</strong></p></td><td><p dir="RTL">٤</p></td><td><p dir="RTL">۱٦۰</p></td><td><p dir="RTL">۱</p></td><td><p dir="RTL">٧٫٤</p></td></tr><tr><td><p dir="RTL">٥</p></td><td><p dir="RTL">۲۰۰</p></td><td><p dir="RTL">١٫۲</p></td><td><p dir="RTL">٨٫٨</p></td></tr><tr><td><p dir="RTL">٦</p></td><td><p dir="RTL">۲٤۰</p></td><td><p dir="RTL">١٫٤</p></td><td><p dir="RTL">۱۰</p></td></tr><tr><td><p dir="RTL">۷</p></td><td><p dir="RTL">۲۸۰</p></td><td><p dir="RTL">١٫٧</p></td><td><p dir="RTL">۱۳</p></td></tr><tr><td><p dir="RTL">۸</p></td><td><p dir="RTL">۳۲۰</p></td><td><p dir="RTL">١٫٩</p></td><td><p dir="RTL">۱٤</p></td></tr><tr><td><p dir="RTL">۹</p></td><td><p dir="RTL">۳٦۰</p></td><td><p dir="RTL">٢٫٢</p></td><td><p dir="RTL">۱٦</p></td></tr><tr><td><p dir="RTL">۱۰</p></td><td><p dir="RTL">٤۰۰</p></td><td><p dir="RTL">٢٫٤</p></td><td><p dir="RTL">۱۸</p></td></tr></tbody></table><p dir="RTL"><sup>١ </sup>بناءً على مكون سيفتازيديم فقط.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحضير جرعات زافيسيفتا (تركيز نهائي ٢٠ ملجم/مل من سيفتازيديم) للمرضى من الأطفال الذين تتراوح أعمارهم بين ٣ أشهر و١٢&nbsp;شهرًا ممن يكون معدل تصفية كرياتينين لديهم بين ٣١ و٥٠ مل/دقيقة/١٫٧٣ م<sup>٢</sup></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p dir="RTL"><strong>العمر وجرعة زافيسيفتا (ملجم/كلجم)<sup>١</sup></strong></p></td><td><p dir="RTL"><strong>الوزن (كلجم)</strong></p></td><td><p dir="RTL"><strong>الجرعة</strong></p><p dir="RTL"><strong>(ملجم سيفتازيديم)</strong></p></td><td><p dir="RTL"><strong>حجم المحلول المُحضَّر المسحوب من القارورة</strong></p><p dir="RTL"><strong>(مل)</strong></p></td><td><p dir="RTL"><strong>حجم المادة المخففة المضاف من أجل المزج (مل)</strong></p></td></tr><tr><td rowspan="8"><p dir="RTL"><strong>من ٦ أشهر إلى</strong></p><p dir="RTL"><strong>١٢ شهرًا</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>٢٥ ملجم/كلجم</strong></p><p dir="RTL"><strong>من سيفتازيديم</strong></p></td><td><p dir="RTL">٥</p></td><td><p dir="RTL">۱۲٥</p></td><td><p dir="RTL">٠٫٧٥</p></td><td><p dir="RTL">٥٫٥</p></td></tr><tr><td><p dir="RTL">٦</p></td><td><p dir="RTL">۱٥۰</p></td><td><p dir="RTL">٠٫٩</p></td><td><p dir="RTL">٦٫٦</p></td></tr><tr><td><p dir="RTL">۷</p></td><td><p dir="RTL">۱۷٥</p></td><td><p dir="RTL">۱</p></td><td><p dir="RTL">٧٫٤</p></td></tr><tr><td><p dir="RTL">۸</p></td><td><p dir="RTL">۲۰۰</p></td><td><p dir="RTL">١٫٢</p></td><td><p dir="RTL">٨٫٨</p></td></tr><tr><td><p dir="RTL">۹</p></td><td><p dir="RTL">۲۲٥</p></td><td><p dir="RTL">١٫٣</p></td><td><p dir="RTL">٩٫٦</p></td></tr><tr><td><p dir="RTL">۱۰</p></td><td><p dir="RTL">۲٥۰</p></td><td><p dir="RTL">١٫٥</p></td><td><p dir="RTL">۱۱</p></td></tr><tr><td><p dir="RTL">۱۱</p></td><td><p dir="RTL">۲۷٥</p></td><td><p dir="RTL">١٫٦</p></td><td><p dir="RTL">۱۲</p></td></tr><tr><td><p dir="RTL">۱۲</p></td><td><p dir="RTL">۳۰۰</p></td><td><p dir="RTL">١٫٨</p></td><td><p dir="RTL">۱۳</p></td></tr><tr><td rowspan="7"><p dir="RTL"><strong>من </strong><strong>۳</strong><strong> أشهر إلى</strong></p><p dir="RTL"><strong>أقل من ٦ أشهر</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>٢٠ ملجم/كلجم</strong></p><p dir="RTL"><strong>من سيفتازيديم</strong></p></td><td><p dir="RTL">٤</p></td><td><p dir="RTL">۸۰</p></td><td><p dir="RTL">٠٫٤٨</p></td><td><p dir="RTL">٣٫٥</p></td></tr><tr><td><p dir="RTL">٥</p></td><td><p dir="RTL">۱۰۰</p></td><td><p dir="RTL">٠٫٦</p></td><td><p dir="RTL">٤٫٤</p></td></tr><tr><td><p dir="RTL">٦</p></td><td><p dir="RTL">۱۲۰</p></td><td><p dir="RTL">٠٫٧٢</p></td><td><p dir="RTL">٥٫٣</p></td></tr><tr><td><p dir="RTL">۷</p></td><td><p dir="RTL">۱٤۰</p></td><td><p dir="RTL">٠٫٨٤</p></td><td><p dir="RTL">٦٫٢</p></td></tr><tr><td><p dir="RTL">۸</p></td><td><p dir="RTL">۱٦۰</p></td><td><p dir="RTL">۱</p></td><td><p dir="RTL">٧٫٤</p></td></tr><tr><td><p dir="RTL">۹</p></td><td><p dir="RTL">۱۸۰</p></td><td><p dir="RTL">١٫١</p></td><td><p dir="RTL">٨٫١</p></td></tr><tr><td><p dir="RTL">۱۰</p></td><td><p dir="RTL">۲۰۰</p></td><td><p dir="RTL">١٫٢</p></td><td><p dir="RTL">٨٫٨</p></td></tr></tbody></table><p dir="RTL"><sup>١ </sup>بناءً على مكون سيفتازيديم فقط.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحضير جرعات زافيسيفتا (تركيز نهائي ٢٠ ملجم/مل من سيفتازيديم) للمرضى من الأطفال الذين تتراوح أعمارهم بين ٣ أشهر و١٢&nbsp;شهرًا ممن يكون معدل تصفية الكرياتينين لديهم بين ١٦ و٣٠ مل/دقيقة/١٫٧٣ م<sup>٢</sup></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p dir="RTL"><strong>العمر وجرعة زافيسيفتا (ملجم/كلجم)<sup> ١</sup></strong></p></td><td><p dir="RTL"><strong>الوزن (كلجم)</strong></p></td><td><p dir="RTL"><strong>الجرعة</strong></p><p dir="RTL"><strong>(ملجم سيفتازيديم)</strong></p></td><td><p dir="RTL"><strong>حجم المحلول المُحضَّر المسحوب من القارورة</strong></p><p dir="RTL"><strong>(مل)</strong></p></td><td><p dir="RTL"><strong>حجم المادة المخففة المضاف من أجل المزج (مل)</strong></p></td></tr><tr><td rowspan="8"><p dir="RTL"><strong>من ٦ أشهر إلى</strong></p><p dir="RTL"><strong>١٢ شهرًا</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>١٨٫٧٥ ملجم/كلجم</strong></p><p dir="RTL"><strong>من سيفتازيديم</strong></p></td><td><p dir="RTL">&rlm;٥&rlm;</p></td><td><p dir="RTL">٩٣٫٧٥</p></td><td><p dir="RTL">٠٫٥٦</p></td><td><p dir="RTL">٤٫١</p></td></tr><tr><td><p dir="RTL">٦</p></td><td><p dir="RTL">١١٢٫٥</p></td><td><p dir="RTL">٠٫٦٧</p></td><td><p dir="RTL">٤٫٩</p></td></tr><tr><td><p dir="RTL">۷</p></td><td><p dir="RTL">١٣١٫٢٥</p></td><td><p dir="RTL">٠٫٧٨</p></td><td><p dir="RTL">٥٫٧</p></td></tr><tr><td><p dir="RTL">۸</p></td><td><p dir="RTL">١٥٠</p></td><td><p dir="RTL">٠٫٩</p></td><td><p dir="RTL">٦٫٦</p></td></tr><tr><td><p dir="RTL">۹</p></td><td><p dir="RTL">١٦٨٫٧٥</p></td><td><p dir="RTL">۱</p></td><td><p dir="RTL">٧٫٤</p></td></tr><tr><td><p dir="RTL">۱۰</p></td><td><p dir="RTL">١٨٧٫٥</p></td><td><p dir="RTL">١٫١</p></td><td><p dir="RTL">٨٫١</p></td></tr><tr><td><p dir="RTL">۱۱</p></td><td><p dir="RTL">٢٠٦٫٢٥</p></td><td><p dir="RTL">١٫٢</p></td><td><p dir="RTL">٨٫٨</p></td></tr><tr><td><p dir="RTL">۱۲</p></td><td><p dir="RTL">۲۲٥</p></td><td><p dir="RTL">١٫٣</p></td><td><p dir="RTL">٩٫٦</p></td></tr><tr><td rowspan="7"><p dir="RTL"><strong>من </strong>٣<strong> أشهر إلى</strong></p><p dir="RTL"><strong>أقل من ٦ أشهر</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>١٥ ملجم/كلجم</strong></p><p dir="RTL"><strong>من سيفتازيديم</strong></p></td><td><p dir="RTL">&rlm;٤&rlm;</p></td><td><p dir="RTL">٦۰</p></td><td><p dir="RTL">٠٫٣٦</p></td><td><p dir="RTL">٢٫٧</p></td></tr><tr><td><p dir="RTL">٥</p></td><td><p dir="RTL">۷٥</p></td><td><p dir="RTL">٠٫٤٥</p></td><td><p dir="RTL">٣٫٣</p></td></tr><tr><td><p dir="RTL">٦</p></td><td><p dir="RTL">۹۰</p></td><td><p dir="RTL">٠٫٥٤</p></td><td><p dir="RTL">٤</p></td></tr><tr><td><p dir="RTL">۷</p></td><td><p dir="RTL">۱۰٥</p></td><td><p dir="RTL">٠٫٦٣</p></td><td><p dir="RTL">٤٫٦</p></td></tr><tr><td><p dir="RTL">۸</p></td><td><p dir="RTL">۱۲۰</p></td><td><p dir="RTL">٠٫٧٢</p></td><td><p dir="RTL">٥٫٣</p></td></tr><tr><td><p dir="RTL">۹</p></td><td><p dir="RTL">۱۳٥</p></td><td><p dir="RTL">٠٫٨١</p></td><td><p dir="RTL">٦</p></td></tr><tr><td><p dir="RTL">۱۰</p></td><td><p dir="RTL">۱٥۰</p></td><td><p dir="RTL">٠٫٩</p></td><td><p dir="RTL">٦٫٦</p></td></tr></tbody></table><p dir="RTL"><sup>١ </sup>بناءً على مكون سيفتازيديم فقط.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>المرضى من الأطفال في سن الولادة (بما في ذلك الخدج) وحتى عمر أقل من &rlm;٣&rlm; أشهر:</u></p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL">ملاحظة: يصف الإجراء التالي خطوات إعداد محلول مخزون مركز مخصص للتسريب ذي تركيز نهائي قدره &rlm;١٠&rlm; ملجم/مل من سيفتازيديم مناسب لإعطاء جرعات أقل من &rlm;٢٥٠&rlm; ملجم للمرضى من الأطفال في سن الولادة (بما في ذلك الخدج) وحتى عمر أقل من &rlm;٣&rlm; أشهر. ويمكن إعداد تركيزات بديلة، لكن يجب أن يبلغ التركيز النهائي من سيفتازيديم &rlm;٨&rlm;-&rlm;٤٠&rlm; ملجم/مل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">١.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جهز <strong>المحلول المُحضَّر (&rlm;١٦٧٫٣&rlm; ملجم/مل</strong> من سيفتازيديم):</p><p dir="RTL">أ&zwnj;)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدخل إبرة المحقنة عبر غطاء القارورة واحقن &rlm;١٠&rlm; مل من الماء المعقم المخصص للحقن.</p><p dir="RTL">ب&zwnj;)&nbsp;&nbsp;&nbsp; اسحب الإبرة ورج القارورة لينتج محلول صاف.</p><p dir="RTL">ج&zwnj;)&nbsp;&nbsp;&nbsp; أدخل إبرة تفريغ غاز عبر غطاء القارورة <strong>بعد</strong> ذوبان المنتج لتخفيف الضغط الداخلي (هذه خطوة مهمة للحفاظ على تعقيم المنتج).</p><p dir="RTL">٢.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جهز <strong>محلول المخزون المركز النهائي</strong> المخصص للتسريب بتركيز نهائي يبلغ <strong>&rlm;١٠&rlm; ملجم/مل</strong> من سيفتازيديم:</p><p dir="RTL">أ&zwnj;)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عليك زيادة معدل تخفيف المحلول المُحضَّر عن طريق نقل &rlm;٣&rlm; مل من المحلول المُحضَّر إلى كيس تسريب أو محقنة تسريب يحتويان على &rlm;٤٧&rlm; مل من المادة المخففة (محلول كلوريد الصوديوم &rlm;٩&rlm; ملجم/مل (&rlm;٠٫٩ &rlm;٪) المخصص للحقن أو محلول ديكستروز &rlm;٥٠&rlm; ملجم/مل (&rlm;٥ &rlm;٪) المخصص للحقن) ليصبح الحجم النهائي &rlm;٥٠&rlm; مل.</p><p dir="RTL">ب&zwnj;)&nbsp;&nbsp;&nbsp; امزج المحلول جيدًا (على سبيل المثال، اقلب كيس التسريب برفق أو استخدم موصل المحاقن لتمرير المحلول برفق بين محقنتين &rlm;٥&rlm; مرات على الأقل).</p><p dir="RTL">ج&zwnj;)&nbsp;&nbsp;&nbsp; انقل حجمًا مناسبًا من محلول المخزون المركز بتركيز &rlm;<strong>١٠&rlm; ملجم/مل</strong> من سيفتازيديم إلى محقنة التسريب. راجع الجدول أدناه لمعرفة حجم محلول المخزون المركز اللازم نقله إلى محقنة التسريب المراد استعمالها. مع العلم أن القيم الموضحة تقريبية، فقد يكون من الضروري التقريب إلى أقرب علامة تدريج موضحة على إحدى المحاقن ذات الحجم المناسب. يرجى ملاحظة أن الجداول لا تشمل جميع الجرعات المحسوبة المحتملة، ولكن يمكن استخدامها لتقدير الحجم التقريبي بهدف التأكد من صحة من الحسابات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحضير جرعات زافيسيفتا للمرضى من الأطفال في سن الولادة (بما في ذلك الخدج) وحتى عمر أقل من &rlm;٣&rlm; أشهر باستخدام محلول المخزون المركز بحجم &rlm;٥٠&rlm;&nbsp;مل من زافيسيفتا (تركيز نهائي &rlm;١٠&rlm; ملجم/مل من سيفتازيديم) الذي يُحضر باستخدام &rlm;٣&rlm;&nbsp;مل من المحلول المُحضَّر المسحوب من القارورة وإضافته إلى &rlm;٤٧&rlm; مل من المادة المخففة.</p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p dir="RTL"><strong>العمر وجرعة زافيسيفتا (ملجم/كلجم)<sup>١</sup></strong></p></td><td><p dir="RTL"><strong>الوزن (كلجم)</strong></p></td><td><p dir="RTL"><strong>الجرعة</strong></p><p dir="RTL"><strong>(ملجم سيفتازيديم)</strong></p></td><td><p dir="RTL"><strong>حجم محلول المخزون المركز &rlm;١٠&rlm; ملجم/مل (سيفتازيديم) المقرر استعماله (مل)</strong></p></td></tr><tr><td rowspan="11"><p dir="RTL">الرضع مكتملو النمو (مدة الحمل تساوي&nbsp;&rlm;٣٧&rlm;&nbsp;أسبوعًا فأكثر) ممن تتراوح أعمارهم بين ما يزيد عن &rlm;٢٨&rlm;&nbsp;يومًا وأقل من&nbsp;&rlm;٣&rlm;&nbsp;أشهر</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">أو</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">الرضع الخدج ممن تزيد أعمارهم عن&nbsp;&rlm;٤٤&rlm;&nbsp;أسبوعًا وتقل عن &rlm;٥٣&rlm; أسبوعًا محسوبة من بداية آخر دورة حيض (PMA)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&rlm;٣٠&rlm; ملجم/كلجم من سيفتازيديم</strong></p></td><td><p dir="RTL">&rlm;٣&rlm;</p></td><td><p dir="RTL">&rlm;٩٠&rlm;</p></td><td><p dir="RTL">&rlm;٩&rlm;</p></td></tr><tr><td><p dir="RTL">&rlm;٣٫٥&rlm;</p></td><td><p dir="RTL">&rlm;١٠٥&rlm;</p></td><td><p dir="RTL">&rlm;١٠٫٥&rlm;</p></td></tr><tr><td><p dir="RTL">&rlm;٤&rlm;</p></td><td><p dir="RTL">&rlm;١٢٠&rlm;</p></td><td><p dir="RTL">&rlm;١٢&rlm;</p></td></tr><tr><td><p dir="RTL">&rlm;٤٫٥&rlm;</p></td><td><p dir="RTL">&rlm;١٣٥&rlm;</p></td><td><p dir="RTL">&rlm;١٣٫٥&rlm;</p></td></tr><tr><td><p dir="RTL">&rlm;٥&rlm;</p></td><td><p dir="RTL">&rlm;١٥٠&rlm;</p></td><td><p dir="RTL">&rlm;١٥&rlm;</p></td></tr><tr><td><p dir="RTL">&rlm;٥٫٥&rlm;</p></td><td><p dir="RTL">&rlm;١٦٥&rlm;</p></td><td><p dir="RTL">&rlm;١٦٫٥&rlm;</p></td></tr><tr><td><p dir="RTL">&rlm;٦&rlm;</p></td><td><p dir="RTL">&rlm;١٨٠&rlm;</p></td><td><p dir="RTL">&rlm;١٨&rlm;</p></td></tr><tr><td><p dir="RTL">&rlm;٦٫٥&rlm;</p></td><td><p dir="RTL">١٩٥</p></td><td><p dir="RTL">١٩٫٥</p></td></tr><tr><td><p dir="RTL">&rlm;٧&rlm;</p></td><td><p dir="RTL">&rlm;٢١٠&rlm;</p></td><td><p dir="RTL">&rlm;٢١&rlm;</p></td></tr><tr><td><p dir="RTL">٧٫٥</p></td><td><p dir="RTL">۲۲٥</p></td><td><p dir="RTL">٢٢٫٥</p></td></tr><tr><td><p dir="RTL">&rlm;٨&rlm;</p></td><td><p dir="RTL">۲٤۰</p></td><td><p dir="RTL">۲٤</p></td></tr><tr><td rowspan="18"><p dir="RTL">حديثو الولادة مكتملو النمو (مدة الحمل تساوي&nbsp;&rlm;٣٧&rlm;&nbsp;أسبوعًا فأكثر) منذ سن الولادة وحتى عمر&nbsp;&rlm;٢٨&rlm;&nbsp;يومًا أو أقل</p><p dir="RTL">أو</p><p dir="RTL">حديثو الولادة الخدج في عمر &rlm;٢٦&rlm; أسبوعًا حتى &rlm;٤٤&rlm;&nbsp;أسبوعًا أو أقل محسوبًا من بداية آخر دورة حيض</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&rlm;٢٠&rlm; ملجم/كلجم من سيفتازيديم</strong></p></td><td><p dir="RTL">٠٫٨</p></td><td><p dir="RTL">۱٦</p></td><td><p dir="RTL">١٫٦</p></td></tr><tr><td><p dir="RTL">١</p></td><td><p dir="RTL">٢٠</p></td><td><p dir="RTL">٢</p></td></tr><tr><td><p dir="RTL">&rlm;١٫٢&rlm;</p></td><td><p dir="RTL">٢٤</p></td><td><p dir="RTL">٢٫٤</p></td></tr><tr><td><p dir="RTL">١٫٤</p></td><td><p dir="RTL">&rlm;٢٨&rlm;</p></td><td><p dir="RTL">&rlm;٢٫٨&rlm;</p></td></tr><tr><td><p dir="RTL">١٫٦</p></td><td><p dir="RTL">۳۲</p></td><td><p dir="RTL">٣٫٢</p></td></tr><tr><td><p dir="RTL">١٫٨</p></td><td><p dir="RTL">۳٦</p></td><td><p dir="RTL">٣٫٦</p></td></tr><tr><td><p dir="RTL">۲</p></td><td><p dir="RTL">٤۰</p></td><td><p dir="RTL">&rlm;٤&rlm;</p></td></tr><tr><td><p dir="RTL">٢٫٢</p></td><td><p dir="RTL">٤٤</p></td><td><p dir="RTL">٤٫٤</p></td></tr><tr><td><p dir="RTL">٢٫٤</p></td><td><p dir="RTL">٤۸</p></td><td><p dir="RTL">٤٫۸</p></td></tr><tr><td><p dir="RTL">٢٫٦</p></td><td><p dir="RTL">٥۲</p></td><td><p dir="RTL">٥٫٢</p></td></tr><tr><td><p dir="RTL">&rlm;٢٫٨&rlm;</p></td><td><p dir="RTL">٥٦</p></td><td><p dir="RTL">٥٫٦</p></td></tr><tr><td><p dir="RTL">&rlm;٣&rlm;</p></td><td><p dir="RTL">&rlm;٦٠&rlm;</p></td><td><p dir="RTL">&rlm;٦&rlm;</p></td></tr><tr><td><p dir="RTL">&rlm;٣٫٥&rlm;</p></td><td><p dir="RTL">&rlm;٧٠&rlm;</p></td><td><p dir="RTL">&rlm;٧&rlm;</p></td></tr><tr><td><p dir="RTL">&rlm;٤&rlm;</p></td><td><p dir="RTL">&rlm;٨٠&rlm;</p></td><td><p dir="RTL">&rlm;٨&rlm;</p></td></tr><tr><td><p dir="RTL">&rlm;٤٫٥&rlm;</p></td><td><p dir="RTL">&rlm;٩٠&rlm;</p></td><td><p dir="RTL">&rlm;٩&rlm;</p></td></tr><tr><td><p dir="RTL">&rlm;٥&rlm;</p></td><td><p dir="RTL">&rlm;١٠٠&rlm;</p></td><td><p dir="RTL">&rlm;١٠&rlm;</p></td></tr><tr><td><p dir="RTL">&rlm;٥٫٥&rlm;</p></td><td><p dir="RTL">&rlm;١١٠&rlm;</p></td><td><p dir="RTL">&rlm;١١&rlm;</p></td></tr><tr><td><p dir="RTL">&rlm;٦&rlm;</p></td><td><p dir="RTL">&rlm;١٢٠&rlm;</p></td><td><p dir="RTL">&rlm;١٢&rlm;</p></td></tr></tbody></table><p dir="RTL"><sup>١&nbsp;</sup>بناءً على مكون سيفتازيديم فقط.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُخزَّن في عبوته الأصلية لحمايته من الضوء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية عبر مياه الصرف أو مع المخلفات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد في حاجة إليها. ستساعد هذه الإجراءات على حماية البيئة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادتان الفعالتان هما سيفتازيديم وأفيباكتام. تحتوي كل قارورة على خماسي هيدرات سيفتازيديم بما يعادل ٢ جرام سيفتازيديم وأفيباكتام صوديوم بما يعادل ٠,٥ جرام أفيباكتام.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي كربونات الصوديوم (اللا مائية) (انظر قسم ٢ &quot;يحتوي زافيسيفتا على الصوديوم&quot;).</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL">زافيسيفتا مسحوق أصفر شاحب لتحضير ركازة لإعداد محلول للتسريب، معبأ في قارورة. وهو متاح في عبوات تحتوي على ١٠ قوارير.</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>مالك رخصة التسويق</strong></p><p dir="RTL">Pfizer Ireland Pharmaceuticals</p><p dir="RTL">Ireland ، إيرلندا</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المصنع</strong></p><p dir="RTL">ACS Dobfar S.p.A</p><p dir="RTL">Italy، إيطاليا</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            أكتوبر/تشرين الأول ٢٠٢٤
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Zavicefta 2 g/0.5 g powder for concentrate for solution for infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial contains ceftazidime pentahydrate equivalent to 2 g ceftazidime and avibactam sodium equivalent to 0.5 g avibactam.

After reconstitution, 1 mL of solution contains 167.3 mg of ceftazidime and 41.8 mg of avibactam (see section 6.6).

Excipient with known effect: Sodium.



For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for concentrate for solution for infusion (powder for concentrate).

A white to pale yellow powder.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Zavicefta is indicated in adults and paediatric patients from birth for the treatment of the following infections (see sections 4.4 and 5.1):</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Complicated intra-abdominal infection (cIAI)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Complicated urinary tract infection (cUTI), including pyelonephritis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP)</p><p>&nbsp;</p><p>Treatment of adult patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.</p><p>&nbsp;</p><p>Zavicefta is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adults and paediatric patients from birth with limited treatment options (see sections 4.2, 4.4 and 5.1).</p><p>&nbsp;</p><p>Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>It is recommended that Zavicefta should be used to treat infections due to aerobic Gram-negative organisms in adults and paediatric patients from birth with limited treatment options only after consultation with a physician with appropriate experience in the management of infectious diseases (see section 4.4).</p><p><u>&nbsp;</u></p><p><u>Posology</u></p><p><u>&nbsp;</u></p><p><em>Dosage in adults with </em><em>c</em><em>reatinine clearance (</em><em>CrCL) &gt;&nbsp;50&nbsp;mL/min</em></p><p><em>&nbsp;</em></p><p>Table 1 shows the recommended intravenous dose for adults with estimated creatinine clearance (CrCL) &gt;&nbsp;50&nbsp;mL/min (see sections 4.4 and 5.1).</p><p>&nbsp;</p><p>Table 1: Recommended dose for adults with estimated CrCL &gt;&nbsp;50&nbsp;mL/min<sup>1</sup></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>Type of infection</p></td><td style="vertical-align:top"><p>Dose of</p><p>ceftazidime/avibactam</p></td><td style="vertical-align:top"><p>Frequency</p></td><td style="vertical-align:top"><p>Infusion time</p></td><td style="vertical-align:top"><p>Duration of treatment</p></td></tr><tr><td style="vertical-align:top"><p>cIAI<sup>2,3</sup></p><p>&nbsp;</p></td><td style="vertical-align:top"><p>2&nbsp;g/0.5&nbsp;g</p></td><td style="vertical-align:top"><p>Every 8&nbsp;hours</p></td><td style="vertical-align:top"><p>2 hours</p></td><td style="vertical-align:top"><p>5-14 days</p></td></tr><tr><td style="vertical-align:top"><p>cUTI, including pyelonephritis<sup>3</sup></p><p>&nbsp;</p></td><td style="vertical-align:top"><p>2&nbsp;g/0.5&nbsp;g</p></td><td style="vertical-align:top"><p>Every 8&nbsp;hours</p></td><td style="vertical-align:top"><p>2 hours</p></td><td style="vertical-align:top"><p>5-10 days<sup>4</sup></p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>HAP/VAP<sup>3</sup></p><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>2&nbsp;g/0.5&nbsp;g</p></td><td style="vertical-align:top"><p>Every 8&nbsp;hours</p></td><td style="vertical-align:top"><p>2 hours</p></td><td style="vertical-align:top"><p>7-14 days</p></td></tr><tr><td style="vertical-align:top"><p>Bacteraemia associated with, or suspected to be associated with any of the above infections</p></td><td style="vertical-align:top"><p>2&nbsp;g/0.5&nbsp;g</p></td><td style="vertical-align:top"><p>Every 8&nbsp;hours</p></td><td style="vertical-align:top"><p>2 hours</p></td><td style="vertical-align:top"><p>Duration of treatment should be in accordance with the site of infection.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Infections due to aerobic Gram-negative organisms in patients with limited treatment options<sup>2,3</sup></p></td><td style="vertical-align:top"><p>2&nbsp;g/0.5&nbsp;g</p></td><td style="vertical-align:top"><p>Every 8&nbsp;hours</p></td><td style="vertical-align:top"><p>2 hours</p></td><td style="vertical-align:top"><p>Guided by the severity of the infection, the pathogen(s) and the patient&rsquo;s clinical and bacteriological progress<sup>5</sup></p></td></tr></tbody></table><p><sup>1</sup> CrCL estimated using the Cockcroft-Gault formula.</p><p><sup>2</sup> To be used in combination with metronidazole when anaerobic pathogens are known or suspected to be contributing to the infectious process.</p><p><sup>3</sup> To be used in combination with an antibacterial agent active against Gram-positive pathogens when these are known or suspected to be contributing to the infectious process.</p><p><sup>4</sup> The total duration shown may include intravenous Zavicefta followed by appropriate oral therapy.</p><p><sup>5 </sup>There is very limited experience with the use of Zavicefta for more than 14 days.</p><p>&nbsp;</p><p><em>Dosage in paediatric patients with creatinine clearance (</em><em>CrCL) </em><em>&gt;&nbsp;</em><em>50&nbsp;mL/min/1.73&nbsp;m<sup>2</sup></em></p><p><em>&nbsp;</em></p><p>Table 2 shows the recommended intravenous doses for paediatric patients with estimated creatinine clearance (CrCL) &gt;&nbsp;50 mL/min/1.73&nbsp;m<sup>2</sup> (see sections 4.4 and 5.1).</p><p>&nbsp;</p><p>Table 2: Recommended dose for paediatric patients from 3 months of age with estimated CrCL<sup>1</sup>&nbsp;&gt;&nbsp;50&nbsp;mL/min/1.73&nbsp;m<sup>2 </sup></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p>Type of infection</p></td><td style="vertical-align:top"><p>Age group<sup>8</sup></p></td><td style="vertical-align:top"><p>Dose of <strong>ceftazidime</strong>/avibactam<sup>7</sup></p></td><td style="vertical-align:top"><p>Frequency</p></td><td style="vertical-align:top"><p>Infusion time<sup> </sup></p></td><td style="vertical-align:top"><p>Duration of treatment</p></td></tr></thead><tbody><tr><td rowspan="3"><p>cIAI<sup>2,3</sup></p><p>OR</p><p>cUTI including pyelonephritis<sup>3</sup></p><p>&nbsp;</p><p>OR</p><p>&nbsp;</p><p>HAP/VAP<sup>3</sup></p><p>&nbsp;</p><p>OR</p><p>&nbsp;</p><p>Infections due to aerobic Gram‑negative organisms in patients with limited treatment options (LTO)<sup>2,3</sup></p></td><td rowspan="2"><p>6 months to &lt;&nbsp;18 years</p><p>&nbsp;</p></td><td rowspan="2"><p><strong>50 mg/kg</strong>/12.5 mg/kg</p><p><strong>to a maximum of</strong></p><p><strong>2 g</strong>/0.5&nbsp;g</p><p>&nbsp;</p></td><td><p>Every 8 hours</p></td><td><p>2 hours</p></td><td rowspan="3" style="vertical-align:top"><p>&nbsp;</p><p>cIAI: 5 &ndash; 14 days</p><p>cUTI<sup>4</sup>: 5 &ndash; 14 days</p><p>HAP/VAP: 7&nbsp;&ndash; 14 days</p><p>LTO: Guided by the severity of the infection, the pathogen(s) and the patient&rsquo;s clinical and bacteriological progress<sup>5</sup></p></td></tr><tr><td><p>Every 8 hours</p></td><td><p>2 hours</p></td></tr><tr><td><p>3 months to &lt;&nbsp;6 months<sup>6</sup></p></td><td><p><strong>40 mg/kg</strong>/10 mg/kg</p></td><td><p>Every 8 hours</p></td><td><p>2 hours</p></td></tr></tbody></table><p><sup>1</sup> CrCL estimated using the Schwartz bedside formula.</p><p><sup>2 </sup>To be used in combination with metronidazole when anaerobic pathogens are known or suspected to be contributing to the infectious process.</p><p><sup>3</sup> To be used in combination with an antibacterial agent active against Gram-positive pathogens when these are known or suspected to be contributing to the infectious process.</p><p><sup>4</sup> The total treatment duration shown may include intravenous Zavicefta followed by appropriate oral therapy.</p><p><sup>5</sup> There is very limited experience with the use of Zavicefta for more than 14 days.</p><p><sup>6 </sup>There is limited experience with the use of Zavicefta in paediatric patients 3 months to &lt;&nbsp;6 months (see section 5.2).</p><p><sup>7</sup> Ceftazidime/avibactam is a combination product in a fixed 4:1 ratio and dosage recommendations are based on the ceftazidime component only (see section 6.6).</p><p><sup>8 </sup>Paediatric patients studied from 3 to 12 months of age were full term (&ge;37 weeks gestation).</p><p>&nbsp;</p><p>Table 3: Recommended dose for paediatric patients less than 3 months of age<sup>9</sup></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p>Type of infection</p></td><td colspan="2" style="vertical-align:top"><p>Age group</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dose of <strong>ceftazidime</strong>/avibactam<sup>5</sup></p></td><td style="vertical-align:top"><p>Frequency</p></td><td style="vertical-align:top"><p>Infusion time<sup> </sup></p></td><td style="vertical-align:top"><p>Duration of treatment</p></td></tr></thead><tbody><tr><td rowspan="5" style="vertical-align:top"><p>cIAI<sup>1,2</sup></p><p>OR</p><p>cUTI including pyelonephritis<sup>2</sup></p><p>&nbsp;</p><p>OR</p><p>&nbsp;</p><p>HAP/VAP<sup>2</sup></p><p>&nbsp;</p><p>OR</p><p>&nbsp;</p><p>Infections due to aerobic Gram‑negative organisms in patients with limited treatment options (LTO)<sup>1,2</sup></p></td><td rowspan="2"><p>Full term neonates and infants</p></td><td><p>&gt;&nbsp;28 days to &lt;&nbsp;3&nbsp;months</p></td><td><p><strong>30 mg/kg</strong>/7.5 mg/kg</p><p>&nbsp;</p></td><td rowspan="2"><p>Every 8&nbsp;hours</p></td><td rowspan="2"><p>2 hours</p></td><td rowspan="5"><p>cIAI: 5&nbsp;&ndash;&nbsp;14&nbsp;days</p><p>cUTI<sup>3</sup>: 5&nbsp;&ndash;&nbsp;14 days</p><p>HAP/VAP: 7&nbsp;&ndash; 14 days</p><p>LTO: Guided by the severity of the infection, the pathogen(s) and the patient&rsquo;s clinical and bacteriological progress<sup>4</sup></p></td></tr><tr><td><p>Birth to &le;&nbsp;28 days</p></td><td><p><strong>20 mg/kg</strong>/5 mg/kg</p><p>&nbsp;</p></td></tr><tr><td rowspan="3"><p>Preterm neonates and infants<sup>6</sup></p></td><td><p>&gt;&nbsp;44 weeks to &lt;&nbsp;53&nbsp;weeks PMA<sup>7</sup></p><p>&nbsp;</p></td><td><p><strong>30 mg/kg</strong>/7.5 mg/kg</p><p>&nbsp;</p></td><td rowspan="2"><p>Every 8&nbsp;hours</p></td><td rowspan="2"><p>2 hours</p></td></tr><tr><td><p>31 to &le;&nbsp;44&nbsp;weeks PMA<sup>7</sup></p></td><td><p><strong>20 mg/kg</strong>/5 mg/kg</p><p>&nbsp;</p></td></tr><tr><td><p>26 to &lt;&nbsp;31&nbsp;weeks PMA<sup>7,8</sup></p></td><td><p><strong>20 mg/kg</strong>/5 mg/kg</p><p><strong>&nbsp;</strong></p></td><td><p>Every 12&nbsp;hours</p></td><td><p>2 hours</p></td></tr></tbody></table><p><sup>1 </sup>To be used in combination with metronidazole when anaerobic pathogens are known or suspected to be contributing to the infectious process.</p><p><sup>2</sup> To be used in combination with an antibacterial agent active against Gram-positive pathogens when these are known or suspected to be contributing to the infectious process.</p><p><sup>3</sup> The total treatment duration shown may include intravenous Zavicefta followed by appropriate oral therapy.</p><p><sup>4</sup> There is very limited experience with the use of Zavicefta for more than 14 days.</p><p><sup>5</sup> Ceftazidime/avibactam is a combination product in a fixed 4:1 ratio and dosage recommendations are based on the ceftazidime component only (see section 6.6).</p><p><sup>6 </sup>Preterm defined as &lt; 37 weeks gestation.</p><p><sup>7 </sup>Postmenstrual age.</p><p><sup>8</sup> Dose recommendations for patients 26 to &lt; 31 weeks PMA are based on pharmacokinetic modelling only (see section 5.2).</p><p><sup>9</sup> Patients with serum creatinine at or below the upper limit of normal for age.</p><p>&nbsp;</p><p>Special populations</p><p>&nbsp;</p><p><em>Elderly</em></p><p>No dosage adjustment is required in elderly patients (see section 5.2).</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>&nbsp;</p><p>Table 4 shows the recommended dose adjustments for adults with estimated CrCL &le;&nbsp;50&nbsp;mL/min (see sections 4.4 and 5.2).</p><p>&nbsp;</p><p><em>Dosage in adults with </em><em>CrCL </em><em>&le;&nbsp;</em><em>50 mL/min</em></p><p>&nbsp;</p><p>Table 4: Recommended dose for adults with estimated CrCL<sup>1</sup> &le; 50&nbsp;mL/min</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p>Age group</p></td><td style="vertical-align:top"><p>Estimated CrCL</p><p>(mL/min)</p></td><td style="vertical-align:top"><p>Dose of ceftazidime/avibactam<sup>2,4</sup></p></td><td style="vertical-align:top"><p>Frequency</p></td><td style="vertical-align:top"><p>Infusion time</p></td></tr></thead><tbody><tr><td rowspan="4" style="vertical-align:top"><p>Adults</p></td><td><p>31-50</p></td><td><p>1&nbsp;g/0.25&nbsp;g</p></td><td><p>Every 8&nbsp;hours</p></td><td rowspan="4"><p>2&nbsp;hours</p></td></tr><tr><td><p>16-30</p></td><td rowspan="3"><p>0.75&nbsp;g/0.1875&nbsp;g</p><p>&nbsp;</p></td><td><p>Every 12&nbsp;hours</p></td></tr><tr><td><p>6-15</p></td><td><p>Every 24&nbsp;hours</p></td></tr><tr><td><p>End Stage Renal Disease including on haemodialysis<sup>3</sup></p><p>&nbsp;</p><p>&nbsp;</p></td><td><p>Every 48&nbsp;hours</p></td></tr></tbody></table><p><sup>1</sup> CrCL estimated using the Cockcroft-Gault formula.</p><p><sup>2</sup> Dose recommendations are based on pharmacokinetic modelling (see section 5.2).</p><p><sup>3</sup> Ceftazidime and avibactam are removed by haemodialysis (see sections 4.9 and 5.2). Dosing of Zavicefta on haemodialysis days should occur after completion of haemodialysis.</p><p><sup>4 </sup>Ceftazidime/avibactam is a combination product in a fixed 4:1 ratio and dosage recommendations are based on the ceftazidime component only (see section 6.6).</p><p><strong>&nbsp;</strong></p><p>Table 5 and Table 6 show the recommended dose adjustments for paediatric patients with estimated CrCL &le;&nbsp;50&nbsp;mL/min/1.73 m<sup>2</sup> according to different age groups (see sections 4.4 and 5.2).</p><p><em>&nbsp;</em></p><p><em>Dosage</em><em> in paediatric patients &ge; 2 years of age with CrCl &le;&nbsp;50&nbsp;mL/min/1.73 m<sup>2</sup></em></p><p><em><sup>&nbsp;</sup></em></p><p>Table 5: Recommended dose for paediatric patients aged 2 years to &lt;&nbsp;18 years with estimated CrCL<sup>1</sup> &le;&nbsp;50&nbsp;mL/min/1.73 m<sup>2</sup></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p>Age group</p></td><td style="vertical-align:top"><p>Estimated CrCL</p><p>(mL/min/1.73 m<sup>2</sup>)</p></td><td style="vertical-align:top"><p>Dose of ceftazidime/avibactam<sup>2,4</sup></p></td><td style="vertical-align:top"><p>Frequency</p></td><td style="vertical-align:top"><p>Infusion time</p></td></tr></thead><tbody><tr><td rowspan="4"><p>Paediatric patients aged 2 years to &lt;&nbsp;18&nbsp;years</p><p>&nbsp;</p></td><td><p>31-50</p></td><td><p>25&nbsp;mg/kg/6.25&nbsp;mg/kg</p><p>to a maximum of</p><p>1 g/0.25 g</p></td><td><p>Every 8&nbsp;hours</p></td><td rowspan="4"><p>2&nbsp;hours</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td></tr><tr><td><p>16-30</p></td><td rowspan="3"><p>18.75&nbsp;mg/kg/4.7&nbsp;mg/kg</p><p>to a maximum of</p><p>0.75 g/0.1875 g</p><p>&nbsp;</p><p>&nbsp;</p></td><td><p>Every 12&nbsp;hours</p></td></tr><tr><td><p>6-15</p></td><td><p>Every 24&nbsp;hours</p></td></tr><tr><td><p>End Stage Renal Disease including on haemodialysis<sup>3</sup></p></td><td><p>Every 48&nbsp;hours</p></td></tr></tbody></table><p><sup>1</sup> CrCL estimated using the Schwartz bedside formula.</p><p><sup>2</sup> Dose recommendations are based on pharmacokinetic modelling (see section 5.2).</p><p><sup>3</sup> Ceftazidime and avibactam are removed by haemodialysis (see sections 4.9 and 5.2). Dosing of Zavicefta on haemodialysis days should occur after completion of haemodialysis.</p><p><sup>4</sup> Ceftazidime/avibactam is a combination product in a fixed 4:1 ratio and dosage recommendations are based on the ceftazidime component only (see section 6.6).</p><p><em>&nbsp;</em></p><p><em>Dosage</em><em> in paediatric patients 3 months to &lt; 2 years of age with CrCl &le;&nbsp;50&nbsp;mL/min/1.73 m<sup>2</sup></em></p><p>&nbsp;</p><p>Table 6: Recommended dose for paediatric patients aged 3 months to &lt;&nbsp;2 years with estimated CrCL<sup>1</sup> &le;&nbsp;50&nbsp;mL/min/1.73 m<sup>2 </sup></p><table border="0" cellspacing="0" cellpadding="0" align="left" style="width:100%"><thead><tr><td style="vertical-align:top"><p>Age group<sup>4</sup></p></td><td style="vertical-align:top"><p>Estimated CrCL (mL/min/1.73 m<sup>2</sup>)</p></td><td style="vertical-align:top"><p>Dose of ceftazidime/avibactam<sup>2,3</sup></p></td><td style="vertical-align:top"><p>Frequency</p></td><td style="vertical-align:top"><p>Infusion time</p></td></tr></thead><tbody><tr><td><p>6 months to &lt;&nbsp;2&nbsp;years</p></td><td rowspan="2"><p>31 to 50</p><p>&nbsp;</p></td><td><p><strong>25</strong><strong> mg/kg</strong>/6.25 mg/kg</p></td><td><p>Every 8&nbsp;hours</p></td><td rowspan="4"><p>2&nbsp;hours</p></td></tr><tr><td><p>3 to &lt;&nbsp;6&nbsp;months</p></td><td><p><strong>20</strong><strong> mg/kg</strong>/5 mg/kg</p></td><td><p>Every 8&nbsp;hours</p></td></tr><tr><td><p>6 months to &lt;&nbsp;2 years</p></td><td rowspan="2"><p>16 to 30</p></td><td><p><strong>18</strong><strong>.75 mg/kg</strong>/4.7 mg/kg</p></td><td><p>Every 12&nbsp;hours</p></td></tr><tr><td><p>3 to &lt;&nbsp;6&nbsp;months</p></td><td><p><strong>15 mg/kg</strong>/3.75 mg/kg</p></td><td><p>Every 12&nbsp;hours</p></td></tr></tbody></table><p><sup>1</sup> Calculated using the Schwartz bedside formula.</p><p><sup>2</sup> Dose recommendations are based on pharmacokinetic modelling (see section 5.2).</p><p><sup>3</sup> Ceftazidime/avibactam is a combination product in a fixed 4:1 ratio and dosage recommendations are based on the ceftazidime component only (see section 6.6).</p><p><sup>4 </sup>Paediatric patients studied from 3 to 12 months of age were full term (&ge; 37 weeks gestation).</p><p>&nbsp;</p><p>There is insufficient information to recommend a dosage regimen for paediatric patients aged 3&nbsp;months to &lt;&nbsp;2 years of age that have a CrCL <em>&lt;&nbsp;</em>16&nbsp;mL/min/1.73&nbsp;m<sup>2</sup>.</p><p>&nbsp;</p><p>There is insufficient information to recommend a dosage regimen for paediatric patients from birth to 3 months of age with signs of renal impairment.</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>No dosage adjustment is required in patients with hepatic impairment (see section 5.2).</p><p>&nbsp;</p><p><u>Method of administration</u></p><p><u>&nbsp;</u></p><p>Intravenous use.</p><p><u>&nbsp;</u></p><p>Zavicefta is administered by intravenous infusion over 120 minutes in an appropriate infusion volume (see section 6.6).</p><p>&nbsp;</p><p>For instructions on reconstitution and dilution of the medicinal product before administration see section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.

Hypersensitivity to any cephalosporin antibacterial agent.

Severe hypersensitivity (e.g. anaphylactic reaction, severe skin reaction) to any other type of β-lactam antibacterial agent (e.g. penicillins, monobactams or carbapenems).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Hypersensitivity reactions</u></p><p>&nbsp;</p><p>Serious and occasionally fatal hypersensitivity reactions are possible (see sections 4.3 and 4.8). In case of hypersensitivity reactions, treatment with Zavicefta must be discontinued immediately and adequate emergency measures must be initiated.</p><p>&nbsp;</p><p>There have been reports of hypersensitivity reactions which progressed to Kounis syndrome (acute allergic coronary arteriospasm that can result in myocardial infarction, see section 4.8).</p><p>&nbsp;</p><p>Before beginning treatment, it should be established whether the patient has a history of hypersensitivity reactions to ceftazidime, to other cephalosporins or to any other type of &beta;-lactam antibacterial agent. Caution should be used if ceftazidime/avibactam is given to patients with a history of non-severe hypersensitivity to penicillins, monobactams or carbapenems.</p><p>&nbsp;</p><p><em><u>Clostridioides difficile - </u></em><u>associated diarrhoea</u></p><p><u>&nbsp;</u></p><p><em>Clostridioides difficile - </em>associated diarrhoea has been reported with ceftazidime/avibactam, and can range in severity from mild to life-threatening. This diagnosis should be considered in patients who present with diarrhoea during or subsequent to the administration of Zavicefta (see section 4.8). Discontinuation of therapy with Zavicefta and the administration of specific treatment for <em>Clostridioides difficile </em>should be considered. Medicinal products that inhibit peristalsis should not be given.</p><p>&nbsp;</p><p><u>Renal impairment</u></p><p><u>&nbsp;</u></p><p>Ceftazidime and avibactam are eliminated via the kidneys, therefore, the dose should be reduced according to the degree of renal impairment (see section 4.2). Neurological sequelae, including tremor, myoclonus, non-convulsive status epilepticus, convulsion, encephalopathy and coma, have occasionally been reported with ceftazidime when the dose has not been reduced in patients with renal impairment.</p><p>&nbsp;</p><p>In patients with renal impairment, close monitoring of estimated creatinine clearance is advised. In some patients, the creatinine clearance estimated from serum creatinine can change quickly, especially early in the course of treatment for the infection.</p><p>&nbsp;</p><p><u>Nephrotoxicity</u></p><p><u>&nbsp;</u></p><p>Concurrent treatment with high doses of cephalosporins and nephrotoxic medicinal products such as aminoglycosides or potent diuretics (e.g. furosemide) may adversely affect renal function.</p><p>&nbsp;</p><p><u>Direct antiglobulin test (DAGT or Coombs test) seroconversion and potential risk of haemolytic anaemia</u></p><p>&nbsp;</p><p>Ceftazidime/avibactam use may cause development of a positive direct antiglobulin test (DAGT<strong><em>,</em></strong> or Coombs test),<strong><em> </em></strong>which may interfere with the cross-matching of blood and/or may cause drug induced immune haemolytic anaemia (see section 4.8). While DAGT seroconversion in patients receiving Zavicefta was very common in clinical studies (the estimated range of seroconversion across Phase&nbsp;3 studies was 3.2% to 20.8% in patients with a negative Coombs test at baseline and at least one follow‑up test), there was no evidence of haemolysis in patients who developed a positive DAGT on treatment. However, the possibility that haemolytic anaemia could occur in association with Zavicefta treatment cannot be ruled out. Patients experiencing anaemia during or after treatment with Zavicefta should be investigated for this possibility.</p><p>&nbsp;</p><p><u>Limitations of the clinical data</u></p><p>&nbsp;</p><p>Clinical efficacy and safety studies of Zavicefta have been conducted in cIAI, cUTI and HAP (including VAP).</p><p>&nbsp;</p><p><em>Complicated intra-abdominal infections in adults</em></p><p>In two studies in patients with cIAI, the most common diagnosis (approximately 42%) was appendiceal perforation or peri-appendiceal abscess. Approximately 87% of patients had APACHE II scores of &le;&nbsp;10 and 4% had bacteraemia at baseline. Death occurred in 2.1% (18/857) of patients who received Zavicefta and metronidazole and in 1.4% (12/863) of patients who received meropenem.</p><p>&nbsp;</p><p>Among a subgroup with baseline CrCL 30 to 50&nbsp;mL/min death occurred in 16.7% (9/54) of patients who received Zavicefta and metronidazole and 6.8% (4/59) of patients who received meropenem. Patients with CrCL 30 to 50&nbsp;mL/min received a lower dose of Zavicefta than is currently recommended for patients in this sub-group.</p><p>&nbsp;</p><p><em>Complicated urinary tract infections in adults</em></p><p>In two studies in patients with cUTI, 381/1091 (34.9%) patients were enrolled with cUTI without pyelonephritis while 710 (65.1%) were enrolled with acute pyelonephritis (mMITT population). A total of 81 cUTI patients (7.4%) had bacteraemia at baseline.</p><p><em>&nbsp;</em></p><p><em>Hospital-acquired pneumonia (including ventilator-associated pneumonia) in adults</em></p><p>In a single study in patients with nosocomial pneumonia 280/808 (34.7%) had VAP and 40/808 (5%) were bacteraemic at baseline.</p><p>&nbsp;</p><p><em>Patients with limited treatment options</em></p><p>The use of ceftazidime/avibactam to treat patients with infections due to Gram-negative aerobic pathogens who have limited treatment options is based on experience with ceftazidime alone and on analyses of the pharmacokinetic-pharmacodynamic relationship for ceftazidime/avibactam (see section&nbsp;5.1).</p><p>&nbsp;</p><p><u>Spectrum of activity of ceftazidime/avibactam</u></p><p><u>&nbsp;</u></p><p>Ceftazidime has little or no activity against the majority of Gram-positive organisms and anaerobes (see sections 4.2 and 5.1). Additional antibacterial agents should be used when these pathogens are known or suspected to be contributing to the infectious process.</p><p>&nbsp;</p><p>The inhibitory spectrum of avibactam includes many of the enzymes that inactivate ceftazidime, including Ambler class A &beta;-lactamases and class C &beta;-lactamases. Avibactam does not inhibit class B enzymes (metallo-&beta;-lactamases) and is not able to inhibit many of the class D enzymes (see section&nbsp;5.1).</p><p><u>&nbsp;</u></p><p><u>Non-susceptible organisms</u></p><p><u>&nbsp;</u></p><p>Prolonged use may result in the overgrowth of non-susceptible organisms (e.g. enterococci, fungi), which may require interruption of treatment or other appropriate measures.</p><p>&nbsp;</p><p><u>Interference with laboratory tests</u></p><p><u>&nbsp;</u></p><p>Ceftazidime may interfere with copper reduction methods (Benedict&#39;s, Fehling&#39;s, Clinitest) for detection of glycosuria leading to false positive results. Ceftazidime does not interfere with enzyme-based tests for glycosuria.</p><p>&nbsp;</p><p><u>Controlled sodium diet</u></p><p>&nbsp;</p><p>This medicinal product contains sodium.</p><p>&nbsp;</p><p>The maximum daily dose of this product is equivalent to 22% of the WHO recommended maximum daily intake for sodium. Zavicefta is considered high in sodium. This should be considered when administering Zavicefta to patients who are on a controlled sodium diet.</p><p>&nbsp;</p><p>Zavicefta may be diluted with sodium-containing solutions (see section 6.6) and this should be considered in relation to the total sodium from all sources that will be administered to the patient.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p><u>&nbsp;</u></p><p>There is a potential risk of overdosing, particularly for paediatric patients from birth to less than 12&nbsp;months of age. Care should be taken when calculating the volume of administration of the dose (see sections 4.9 and 6.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>In vitro</em>, avibactam is a substrate of OAT1 and OAT3 transporters which might contribute to the active uptake of avibactam from the blood compartment and, therefore, affect its excretion. Probenecid (a potent OAT inhibitor) inhibits this uptake by 56% to 70% <em>in vitro</em> and, therefore, has the potential to alter the elimination of avibactam. Since a clinical interaction study of avibactam and probenecid has not been conducted, co-administration of avibactam with probenecid is not recommended.</p><p>&nbsp;</p><p>Avibactam showed no significant inhibition of cytochrome P450 enzymes <em>in vitro</em>. Avibactam and ceftazidime showed no <em>in vitro</em> cytochrome P450 induction at clinically relevant concentrations. Avibactam and ceftazidime do not inhibit the major renal or hepatic transporters in the clinically relevant exposure range, therefore the interaction potential via these mechanisms is considered to be low.</p><p>&nbsp;</p><p>Clinical data have demonstrated that there is no interaction between ceftazidime and avibactam, and between ceftazidime/avibactam and metronidazole.</p><p>&nbsp;</p><p><em>Other types of interaction</em></p><p>Concurrent treatment with high doses of cephalosporins and nephrotoxic medicinal products such as aminoglycosides or potent diuretics (e.g. furosemide) may adversely affect renal function (see section&nbsp;4.4).</p><p>&nbsp;</p><p>Chloramphenicol is antagonistic <em>in vitro</em> with ceftazidime and other cephalosporins. The clinical relevance of this finding is unknown, but due to the possibility of antagonism <em>in vivo</em> this drug combination should be avoided.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>&nbsp;</p><p>Animal studies with ceftazidime do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development. Animal studies with avibactam have shown reproductive toxicity without evidence of teratogenic effects (see section 5.3).</p><p>&nbsp;</p><p>Ceftazidime/avibactam should only be used during pregnancy if the potential benefit outweighs the possible risk.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>Ceftazidime is excreted in human milk in small quantities. It is unknown whether avibactam is excreted in human milk. A risk to newborns/infants cannot be excluded. A decision must be made whether to discontinue breast feeding or to discontinue/abstain from ceftazidime/avibactam therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>The effects of ceftazidime/avibactam on fertility in humans have not been studied. No data are available on animal studies with ceftazidime. Animal studies with avibactam do not indicate harmful effects with respect to fertility (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Undesirable effects may occur (e.g. dizziness), which may influence the ability to drive and use machines following administration of Zavicefta (see section 4.8).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><u>Summary of the safety profile</u></p><p><u>&nbsp;</u></p><p>In seven Phase 2 and Phase 3 clinical trials,<em> </em>2024 adults were treated with Zavicefta. The most common adverse reactions occurring in &ge;5% of patients treated with Zavicefta were Coombs direct test positive, nausea, and diarrhoea. Nausea and diarrhoea were usually mild or moderate in intensity.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p><u>&nbsp;</u></p><p>The following adverse reactions have been reported with ceftazidime alone and/or identified during the Phase 2 and Phase 3 trials with Zavicefta. Adverse reactions are classified according to frequency and System Organ Class. Frequency categories are derived from adverse reactions and/or potentially clinically significant laboratory abnormalities, and are defined according to the following conventions:</p><p>&nbsp;</p><p>Very common (&ge;1/10)</p><p>Common (&ge;1/100 and &lt;1/10)</p><p>Uncommon (&ge;1/1,000 and &lt;1/100)</p><p>Rare (&ge;1/10,000 and &lt;1/1000)</p><p>Very rare (&lt;1/10,000)</p><p>Not known (cannot be estimated from the available data)</p><p>&nbsp;</p><p>Table 7: Frequency of adverse reactions by system organ class</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Very common</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Very rare</strong></p></td><td style="vertical-align:top"><p><strong>Not known</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Candidiasis (including Vulvovaginal candidiasis and Oral candidiasis)</p></td><td style="vertical-align:top"><p>Clostridioides difficile colitis</p><p>&nbsp;</p><p>Pseudomembranous colitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Coombs direct test positive</p></td><td style="vertical-align:top"><p>Eosinophilia</p><p>&nbsp;</p><p>Thrombocytosis</p><p>&nbsp;</p><p>Thrombocytopenia</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Neutropenia</p><p>&nbsp;</p><p>Leukopenia</p><p>&nbsp;</p><p>Lymphocytosis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Agranulocytosis</p><p>&nbsp;</p><p>Haemolytic anaemia</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaphylactic reaction</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Headache</p><p>&nbsp;</p><p>Dizziness</p></td><td style="vertical-align:top"><p>Paraesthesia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Kounis syndrome<sup>a,*</sup></p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Diarrhoea</p><p>&nbsp;</p><p>Abdominal pain</p><p>&nbsp;</p><p>Nausea</p><p>&nbsp;</p><p>Vomiting</p></td><td style="vertical-align:top"><p>Dysgeusia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Alanine aminotransferase increased</p><p>&nbsp;</p><p>Aspartate aminotransferase increased</p><p>&nbsp;</p><p>Blood alkaline phosphatase increased</p><p>&nbsp;</p><p>Gamma-glutamyltransferase increased</p><p>&nbsp;</p><p>Blood lactate dehydrogenase</p><p>Increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Jaundice</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rash maculo-papular</p><p>&nbsp;</p><p>Urticaria</p><p>&nbsp;</p><p>Pruritus</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Toxic epidermal necrolysis</p><p>&nbsp;</p><p>Stevens-Johnson syndrome</p><p>&nbsp;</p><p>Erythema multiforme</p><p>&nbsp;</p><p>Angioedema</p><p>&nbsp;</p><p>Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Blood creatinine increased</p><p>&nbsp;</p><p>Blood urea increased</p><p>&nbsp;</p><p>Acute kidney injury</p></td><td style="vertical-align:top"><p>Tubulointerstitial nephritis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p><p><u>&nbsp;</u></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Infusion site thrombosis</p><p>&nbsp;</p><p>Infusion site phlebitis</p><p>&nbsp;</p><p>Pyrexia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><sup>* </sup>ADR identified post-marketing.</p><p><sup>a </sup>Acute coronary syndrome associated with an allergic reaction.</p><p><strong><em>&nbsp;</em></strong></p><p><u>Paediatric population</u></p><p><em>&nbsp;</em></p><p><em>From birth to less than 3 months of age</em></p><p>The safety assessment in neonates and infants less than 3 months of age is based on the safety data from one clinical trial in which 46 patients (from birth to less than 3 months of age) received Zavicefta. Overall, the adverse reactions reported in these 46 paediatric patients were consistent with the known safety profile of Zavicefta in older populations (i.e., paediatric patients from 3 months of age and adults).</p><p><u>&nbsp;</u></p><p><em>3 months of age and older</em></p><p>The safety assessment in paediatric patients from 3 months of age and older is based on the safety data from two trials in which 61&nbsp;patients (aged from 3 years to less than 18 years) with cIAI and 67 patients with cUTI (aged from 3&nbsp;months to less than 18 years) received Zavicefta. Overall, the safety profile in these 128 paediatric patients was similar to that observed in the adult population with cIAI and cUTI.</p><p><u>&nbsp;</u></p><p><u>Reporting of suspected adverse reactions</u></p><p><u>&nbsp;</u></p><p>Reporting suspected adverse reactions after marketing authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to National Pharmacovigilance Center (NPC).</p><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>National Pharmacovigilance Center (NPC)</strong></p><p>SFDA Call center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" align="left" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Overdose with ceftazidime/avibactam can lead to neurological sequelae including encephalopathy, convulsions and coma, due to the ceftazidime component.</p><p>&nbsp;</p><p>Serum levels of ceftazidime can be reduced by haemodialysis or peritoneal dialysis. During a 4-hour haemodialysis period, 55% of the avibactam dose was removed.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antibacterials for systemic use, other beta-lactam antibacterials, third‑generation cephalosporins, ATC code: J01DD52</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p><strong>&nbsp;</strong></p><p>Ceftazidime inhibits bacterial peptidoglycan cell wall synthesis following binding to penicillin binding proteins (PBPs), which leads to bacterial cell lysis and death. Avibactam is a non &beta;-lactam, &beta;‑lactamase inhibitor that acts by forming a covalent adduct with the enzyme that is stable to hydrolysis. It inhibits both Ambler class A and class C &beta;-lactamases and some class D enzymes, including extended-spectrum &beta;-lactamases (ESBLs), KPC and OXA-48 carbapenemases, and AmpC enzymes. Avibactam does not inhibit class B enzymes (metallo-&beta;-lactamases) and is not able to inhibit many class D enzymes.</p><p><strong><em>&nbsp;</em></strong></p><p><u>Resistance</u></p><p>&nbsp;</p><p>Bacterial resistance mechanisms that could potentially affect ceftazidime/avibactam include mutant or acquired PBPs, decreased outer membrane permeability to either compound, active efflux of either compound, and &beta;-lactamase enzymes refractory to inhibition by avibactam and able to hydrolyse ceftazidime.</p><p><u>&nbsp;</u></p><p><u>Antibacterial activity in combination with other antibacterial agents</u></p><p><u>&nbsp;</u></p><p>No synergy or antagonism was demonstrated in <em>in vitro</em> drug combination studies with ceftazidime/avibactam and metronidazole, tobramycin, levofloxacin, vancomycin, linezolid, colistin and tigecycline.</p><p><u>&nbsp;</u></p><p><u>Susceptibility testing breakpoints</u></p><p>&nbsp;</p><p>Minimum Inhibitory Concentration (MIC) breakpoints established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) for ceftazidime/avibactam can be viewed on the following website:</p><p>&nbsp;</p><p>https://www.ema.europa.eu/documents/other/minimum-inhibitory-concentration-mic-breakpoints_en.xlsx</p><p><u>&nbsp;</u></p><p><u>Pharmacokinetic/pharmacodynamic relationship</u></p><p><u>&nbsp;</u></p><p>The antimicrobial activity of ceftazidime against specific pathogens has been shown to best correlate with the percent time of free-drug concentration above the ceftazidime/avibactam minimum inhibitory concentration over the dose interval (%&nbsp;<em>f</em>T &gt;MIC of ceftazidime/avibactam). For avibactam the PK-PD index is the percent time of the free drug concentration above a threshold concentration over the dose interval (%&nbsp;<em>f</em>T &gt;C<sub>T</sub>).</p><p>&nbsp;</p><p><u>Clinical efficacy against specific pathogens</u></p><p><u>&nbsp;</u></p><p>Efficacy has been demonstrated in clinical studies against the following pathogens that were susceptible to ceftazidime/avibactam <em>in vitro</em>.</p><p>&nbsp;</p><p><strong>Complicated intra-abdominal infections</strong></p><p>Gram-negative micro-organisms</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Citrobacter freundii</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Enterobacter cloacae</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Escherichia coli</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Klebsiella oxytoca</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Klebsiella pneumoniae</em></p><ul><li><em>Pseudomonas aeruginosa</em></li></ul><p>&nbsp;</p><p><strong>Complicated urinary-tract infections</strong></p><p>Gram-negative micro-organisms</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Escherichia coli </em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Klebsiella pneumoniae </em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Proteus mirabilis</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Enterobacter cloacae</em></p><ul><li><em>Pseudomonas aeruginosa</em></li></ul><p>&nbsp;</p><p><strong>Hospital-acquired pneumonia including ventilator-associated pneumonia</strong></p><p>Gram-negative micro-organisms</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Enterobacter cloacae</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Escherichia coli</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Klebsiella pneumoniae </em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Proteus mirabilis</em></p><ul><li><em>Serratia marcescens</em></li><li><em>Pseudomonas aeruginosa</em></li></ul><p>&nbsp;</p><p>Clinical efficacy has not been established against the following pathogens that are relevant to the approved indications although <em>in vitro</em> studies suggest that they would be susceptible to ceftazidime/avibactam in the absence of acquired mechanisms of resistance.</p><p>&nbsp;</p><p>Gram-negative micro-organisms</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Citrobacter koseri</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Enterobacter aerogenes</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Morganella morganii</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Proteus </em><em>vulgaris</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Providencia rettgeri</em></p><p><em>&nbsp;</em></p><p><em>In vitro</em> data indicate that the following species are not susceptible to ceftazidime/avibactam.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Staphylococcus aureus</em> (methicillin-susceptible and methicillin-resistant)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anaerobes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Enterococcus </em>spp.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Stenotrophomonas maltophilia</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Acinetobacter </em>spp.</p><p><u>Paediatric population</u></p><p><em>&nbsp;</em></p><p><em>From birth to less than 3 months of age</em></p><p>Zavicefta has been evaluated in paediatric patients from birth to less than 3 months of age in a Phase 2a, 2-part (Part A and B), open-label, non-randomised clinical study in patients with suspected or confirmed infections due to Gram-negative pathogens. Part A used a single dose to assess the pharmacokinetic (PK) profile (primary objective) and evaluate safety and tolerability (secondary objective) of ceftazidime/avibactam. Part B used multiple doses to evaluate the safety and tolerability (primary objective) while the PK profile and efficacy were secondary objectives. Efficacy was only a descriptive endpoint. Clinical cure or clinical improvement rates in Part B were 81.0% (17/21) at TOC (ITT) and 75.0% (12/16) at TOC (modified-ITT). The microbiological eradication or presumed eradication rate at TOC (micro-ITT) was 80% (8/10).</p><p>&nbsp;</p><p><em>3 months of age and older</em></p><p>Zavicefta has been evaluated in paediatric patients aged 3 months to &lt;&nbsp;18 years in two Phase&nbsp;2 single‑blind, randomised, comparative clinical studies, one in patients with cIAI and one in patients with cUTI. The primary objective in each study was to assess safety and tolerability of ceftazidime‑avibactam (+/- metronidazole). Secondary objectives included assessment of pharmacokinetics and efficacy; efficacy was a descriptive endpoint in both studies. Clinical cure rate at TOC (ITT) was 91.8%&nbsp;(56/61) for Zavicefta compared to 95.5%&nbsp;(21/22) for meropenem in paediatric patients with cIAI. Microbiological eradication rate at TOC (micro‑ITT) was 79.6%&nbsp;(43/54) for Zavicefta compared to 60.9%&nbsp;(14/23) for cefepime in paediatric patients with cUTI.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Distribution</u></p><p><u>&nbsp;</u></p><p>The human protein binding of both ceftazidime and avibactam is approximately 10% and 8%, respectively. The steady-state volumes of distribution of ceftazidime and avibactam were about 17&nbsp;L and 22&nbsp;L, respectively in healthy adults following multiple doses of 2&nbsp;g/0.5&nbsp;g ceftazidime/avibactam infused over 2 hours every 8 hours. Both ceftazidime and avibactam penetrate into human bronchial epithelial lining fluid (ELF) to the same extent with concentrations around 30% of those in plasma. The concentration time profiles are similar for ELF and plasma.</p><p>&nbsp;</p><p>Penetration of ceftazidime into the intact blood-brain barrier is poor. Ceftazidime concentrations of 4&nbsp;to 20&nbsp;mg/L or more are achieved in the CSF when the meninges are inflamed. Avibactam penetration of the blood brain barrier has not been studied clinically; however, in rabbits with inflamed meninges, CSF exposures of ceftazidime and avibactam were 43% and 38% of plasma AUC, respectively. Ceftazidime crosses the placenta readily, and is excreted in the breast milk.</p><p><u>&nbsp;</u></p><p><u>Biotransformation</u></p><p><u>&nbsp;</u></p><p>Ceftazidime is not metabolised. No metabolism of avibactam was observed in human liver preparations (microsomes and hepatocytes). Unchanged avibactam was the major drug-related component in human plasma and urine following dosing with [<sup>14</sup>C]-avibactam.</p><p><u>&nbsp;</u></p><p><u>Elimination</u></p><p><u>&nbsp;</u></p><p>The terminal half-life (t<sub>&frac12;</sub>) of both ceftazidime and avibactam is about 2&nbsp;h after intravenous administration. Ceftazidime is excreted unchanged into the urine by glomerular filtration; approximately 80-90% of the dose is recovered in the urine within 24&nbsp;h. Avibactam is excreted unchanged into the urine with a renal clearance of approximately 158 mL/min, suggesting active tubular secretion in addition to glomerular filtration. Approximately 97% of the avibactam dose is recovered in the urine, 95% within 12&nbsp;h. Less than 1% of ceftazidime is excreted via the bile and less than 0.25% of avibactam is excreted into faeces.</p><p>&nbsp;</p><p><u>Linearity/non-linearity</u></p><p><u>&nbsp;</u></p><p>The pharmacokinetics of both ceftazidime and avibactam are approximately linear across the dose range studied (0.05&nbsp;g to 2&nbsp;g) for a single intravenous administration. No appreciable accumulation of ceftazidime or avibactam was observed following multiple intravenous infusions of 2&nbsp;g/0.5&nbsp;g of ceftazidime/avibactam administered every 8 hours for up to 11 days in healthy adults with normal renal function.</p><p><u>&nbsp;</u></p><p><u>Special populations</u></p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>Elimination of ceftazidime and avibactam is decreased in patients with moderate or severe renal impairment. The average increases in avibactam AUC are 3.8-fold and 7-fold in subjects with moderate and severe renal impairment, see section 4.2.</p><p>&nbsp;</p><p><em>Hepatic </em><em>impairment</em></p><p>Mild to moderate hepatic impairment had no effect on the pharmacokinetics of ceftazidime in individuals administered 2&nbsp;g intravenously every 8 hours for 5 days, provided renal function was not impaired. The pharmacokinetics of ceftazidime in patients with severe hepatic impairment has not been established. The pharmacokinetics of avibactam in patients with any degree of hepatic impairment has not been studied.</p><p>&nbsp;</p><p>As ceftazidime and avibactam do not appear to undergo significant hepatic metabolism, the systemic clearance of either active substance is not expected to be significantly altered by hepatic impairment.</p><p>&nbsp;</p><p><em>Elderly patients (&ge;&nbsp;65 years)</em></p><p>Reduced clearance of ceftazidime was observed in elderly patients, which was primarily due to age‑related decrease in renal clearance of ceftazidime. The mean elimination half-life of ceftazidime ranged from 3.5 to 4 hours following intravenous bolus dosing with 2&nbsp;g every 12 hours in elderly patients aged 80 years or older.</p><p>&nbsp;</p><p>Following a single intravenous administration of 500&nbsp;mg avibactam as a 30-minute IV infusion, the elderly had a slower terminal half-life of avibactam, which may be attributed to age related decrease in renal clearance.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The pharmacokinetics of ceftazidime and avibactam were evaluated in paediatric patients from 3&nbsp;months to &lt;&nbsp;18 years of age with suspected or confirmed infections following a single dose of ceftazidime 50&nbsp;mg/kg and avibactam 12.5&nbsp;mg/kg for patients weighing &lt;&nbsp;40&nbsp;kg or Zavicefta 2&nbsp;g/0.5&nbsp;g (ceftazidime 2&nbsp;grams and avibactam 0.5&nbsp;grams) for patients weighing &ge;&nbsp;40&nbsp;kg. Plasma concentrations of ceftazidime and avibactam were similar across all four age cohorts in the study (3 months to &lt;&nbsp;2&nbsp;years, 2 to &lt;&nbsp;6 years, 6 to &lt;&nbsp;12 years, and 12 to &lt;&nbsp;18 years). Ceftazidime and avibactam AUC<sub>0-t</sub> and C<sub>max </sub>values in the two older cohorts (paediatric patients from 6 to &lt;&nbsp;18 years), which had more extensive pharmacokinetic sampling, were similar to those observed in healthy adult subjects with normal renal function that received Zavicefta 2&nbsp;g/0.5&nbsp;g. Data from this study and the two Phase&nbsp;2 paediatric studies in patients with cIAI and cUTI were pooled with PK data from adults (Phase 1 to Phase 3) to update the population PK model, which was used to conduct simulations to assess PK/PD target attainment. Results from these simulations demonstrated that the recommended dose regimens for paediatric patients with cIAI, cUTI and HAP/VAP, including dose adjustments for patients with renal impairment, result in systemic exposure and PK/PD target attainment values that are similar to those in adults at the approved Zavicefta dose of 2&nbsp;g/0.5&nbsp;g administered over 2 hours, every 8 hours.</p><p>&nbsp;</p><p>There is limited experience with the use of ceftazidime plus avibactam in the paediatric groups of 3&nbsp;months to &lt;&nbsp;6 months. The recommended dosing regimens are based on simulations conducted using the final population PK models. Simulations demonstrated that the recommended dose regimens result in comparable exposures to other age groups with PK/PD target attainment &gt;&nbsp;90%. Based on data from the completed paediatric clinical trials, at the recommended dose regimens, there was no evidence of over or under exposure in the subjects aged 3 months to &lt;&nbsp;6 months.</p><p>&nbsp;</p><p>In addition, there is very limited data in paediatric patients aged 3 months to &lt;&nbsp;2 years with impaired renal function (CrCL &le;&nbsp;50&nbsp;mL/min/1.73&nbsp;m<sup>2</sup>), with no data in severe renal impairment from the completed paediatric clinical trials. Population PK models for ceftazidime and avibactam were used to conduct simulations for patients with impaired renal function.</p><p><strong>&nbsp;</strong></p><p>The pharmacokinetics of ceftazidime and avibactam were evaluated in 45 paediatric patients from birth to less than 3 months of age with suspected or confirmed infections following single and multiple doses of ceftazidime 20&nbsp;mg/kg and avibactam 5&nbsp;mg/kg for patients from birth to 28 days (including preterm neonates) or ceftazidime 30 mg/kg and avibactam 7.5&nbsp;mg/kg for patients one month to less than 3 months. Plasma concentrations of ceftazidime and avibactam were similar across all age cohorts. Data from this study was used to update the previous population PK model and perform simulations to assess PK/PD target attainment. These simulations demonstrated that the recommended dose regimens for term neonates (gestational age [GA] &ge;&nbsp;37 weeks), preterm neonates (GA 26 weeks to &lt; 31 weeks and GA 31 to &lt;&nbsp;37 weeks) and infants aged 28 days to &lt;&nbsp;3 months, result in systemic exposure and PK/PD target attainment values that are similar to those in adults at the approved Zavicefta dose of 2&nbsp;g/0.5&nbsp;g administered over 2 hours, every 8 hours. There is no data in pre‑term infants under 31 weeks GA from the completed paediatric clinical trials and dose recommendations in this age group are exclusively based on pharmacokinetic modelling.</p><p><strong>&nbsp;</strong></p><p><em>Gender and race</em></p><p>The pharmacokinetics of ceftazidime/avibactam is not significantly affected by gender or race.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Ceftazidime</u></p><p><u>&nbsp;</u></p><p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, reproduction toxicity or genotoxicity. Carcinogenicity studies have not been conducted with ceftazidime.</p><p>&nbsp;</p><p><u>Avibactam</u></p><p><u>&nbsp;</u></p><p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity or genotoxicity. Carcinogenicity studies have not been conducted with avibactam.</p><p>&nbsp;</p><p><u>Reproduction toxicity</u></p><p><u>&nbsp;</u></p><p>In pregnant rabbits administered avibactam at 300 and 1000&nbsp;mg/kg/day, there was a dose-related lower mean foetal weight and delayed ossification, potentially related to maternal toxicity. Plasma exposure levels at maternal and foetal NOAEL (100&nbsp;mg/kg/day) indicate moderate to low margins of safety.</p><p>&nbsp;</p><p>In the rat, no adverse effects were observed on embryofetal development or fertility. Following administration of avibactam throughout pregnancy and lactation in the rat, there was no effect on pup survival, growth or development, however there was an increase in incidence of dilation of the renal pelvis and ureters in less than 10% of the rat pups at maternal exposures greater than or equal to approximately 1.5 times human therapeutic exposures.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium carbonate (anhydrous)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The compatibility of Zavicefta with other medicines has not been established. Zavicefta should not be mixed with or physically added to solutions containing other medicinal products.</p><p>&nbsp;</p><p>This medicinal product must not be mixed with other medicinal products except those mentioned in section&nbsp;6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Do not use Zavicefta after the expiry date which is stated on the Vial label after EXP:. The expiry date refers to the last day of that month.

Dry powder

3 years.

After reconstitution

The reconstituted vial should be used immediately.

After dilution

Infusion bags
If the intravenous solution is prepared with diluents listed in section 6.6 (ceftazidime concentration 8 mg/mL), the chemical and physical in-use stability has been demonstrated (from initial vial puncture) for up to 12 hours at 2   8°C, followed by up to 4 hours at not more than 25°C.

If the intravenous solution is prepared with diluents listed in section 6.6 (ceftazidime concentration > 8 mg/mL to 40 mg/mL), the chemical and physical in-use stability has been demonstrated (from initial vial puncture) for up to 4 hours at not more than 25°C.

From a microbiological point of view, the medicinal product should be used immediately, unless reconstitution and dilution have taken place in controlled and validated aseptic conditions. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and must not exceed those stated above.

Infusion syringes
If the intravenous solution is prepared with diluents listed in section 6.6 (ceftazidime concentration ≥ 8 mg/mL to 40 mg/mL), the chemical and physical in-use stability has been demonstrated (from initial vial puncture) for up to 6 hours at not more than 25°C.

From a microbiological point of view, the medicinal product should be used immediately unless reconstitution and dilution have taken place in controlled and validated aseptic conditions. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and must not exceed 6 hours at not more than 25°C.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30C.</p><p>&nbsp;</p><p>Store in the original package in order to protect from light.</p><p>&nbsp;</p><p>For storage conditions of the reconstituted and diluted medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>20&nbsp;mL glass vial (Type 1) closed with a rubber (halobutyl) stopper and aluminium seal with flip-off cap.</p><p>&nbsp;</p><p>The medicinal product is supplied in packs of 10 vials.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>Keep out of reach of children</p><p>&nbsp;</p><p>The powder must be reconstituted with water for injections and the resulting concentrate must then be immediately diluted prior to use. The reconstituted solution is a pale yellow solution and is free of particles.&nbsp;</p><p>&nbsp;</p><p>Zavicefta (ceftazidime/avibactam) is a combination product; each vial contains 2&nbsp;g of ceftazidime and 0.5&nbsp;g of avibactam in a fixed 4:1 ratio. Dosage recommendations are based on the ceftazidime component only.</p><p>&nbsp;</p><p>Standard aseptic techniques should be used for solution preparation and administration. Doses may be prepared in an appropriately sized infusion bag or infusion syringe.</p><p>&nbsp;</p><p>Parenteral medicinal products should be inspected visually for particulate matter prior to administration.</p><p>&nbsp;</p><p>Each vial is for single use only.</p><p>&nbsp;</p><p>Any unused product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p><p>The total time interval between starting reconstitution and completing preparation of the intravenous infusion should not exceed 30&nbsp;minutes.</p><p><u>&nbsp;</u></p><p><u>Instructions for preparing adult and paediatric doses in INFUSION BAG or in INFUSION SYRINGE </u></p><p>&nbsp;</p><p>NOTE: The following procedure describes the steps to prepare an infusion solution with a final concentration of 8-40 mg/mL of ceftazidime. All calculations should be completed prior to initiating these steps.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>For paediatric patients 3 to 12 months of age</strong>, detailed steps to prepare a 20 mg/mL concentration (sufficient for most scenarios) are provided below.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>For paediatric patients from birth (including preterm) to &lt; 3 months of age</strong>,<strong> </strong>detailed steps to prepare a<strong> 10&nbsp;mg/mL concentration </strong>(sufficient for most scenarios) are provided below.</p><p>&nbsp;</p><p>1.&nbsp;&nbsp; Prepare the <strong>reconstituted solution</strong> (<strong>167.3 mg/mL</strong> of ceftazidime):</p><p>a)&nbsp;&nbsp;&nbsp;&nbsp; Insert the syringe needle through the vial closure and inject 10&nbsp;mL of sterile water for injections.</p><p>b)&nbsp;&nbsp;&nbsp;&nbsp; Withdraw the needle and shake the vial to give a clear solution.</p><p>c)&nbsp;&nbsp;&nbsp;&nbsp; Insert a gas relief needle through the vial closure <strong>after</strong> the product has dissolved to relieve the internal pressure (this is important to preserve product sterility).</p><p>2.&nbsp;&nbsp; Prepare the <strong>final solution</strong> for infusion (final concentration must be <strong>8-40 mg/mL</strong> of ceftazidime):</p><p>a)&nbsp;&nbsp;&nbsp;&nbsp; Infusion bag: Further dilute the reconstituted solution by transferring an appropriately calculated volume of the reconstituted solution to an infusion bag containing any of the following: sodium chloride 9 mg/mL (0.9%) solution for injection, dextrose 50 mg/mL (5%) solution for injection, or Lactated Ringer&rsquo;s solution.</p><p>b)&nbsp;&nbsp;&nbsp;&nbsp; Infusion syringe: Further dilute the reconstituted solution by transferring an appropriately calculated volume of the reconstituted solution combined with a sufficient volume of diluent (sodium chloride 9 mg/mL (0.9%) solution for injection or dextrose 50 mg/mL (5%) solution for injection) to an infusion syringe.</p><p>&nbsp;</p><p>Refer to Table 8 below.</p><p>&nbsp;</p><p>Table 8: Preparation of Zavicefta for adult and paediatric doses in INFUSION BAG or in INFUSION SYRINGE.</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p><strong>Zavicefta</strong></p><p><strong>dose</strong><strong> (ceftazidime)<sup>1</sup></strong></p></td><td style="vertical-align:top"><p><strong>Volume to withdraw from reconstituted vial</strong></p></td><td style="vertical-align:top"><p><strong>Final volume after dilution in infusion bag<sup>2</sup></strong></p></td><td style="vertical-align:top"><p><strong>Final volume in infusion syringe<sup>3</sup></strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>2 g</p></td><td><p>Entire contents (approximately 12 mL)</p></td><td><p>50 mL to 250 mL</p></td><td><p>50 mL</p></td></tr><tr><td style="vertical-align:top"><p>1 g</p></td><td><p>6 mL</p></td><td><p>25 mL to 125 mL</p></td><td><p>25 mL to 50 mL</p></td></tr><tr><td style="vertical-align:top"><p>0.75 g</p></td><td><p>4.5 mL</p></td><td><p>19 mL to 93 mL</p></td><td><p>19 mL to 50 mL</p></td></tr><tr><td style="vertical-align:top"><p>All other doses</p></td><td><p>Volume (mL) calculated based on dose required:</p><p>&nbsp;</p><p><strong>Dose (mg ceftazidime) </strong><strong>&divide; 167.3 mg/mL ceftazidime</strong></p><p>&nbsp;</p></td><td><p>Volume (mL) will vary based on infusion bag size availability and preferred final concentration</p><p>(must be 8-40 mg/mL of ceftazidime)</p></td><td><p>Volume (mL) will vary based on infusion syringe size availability and preferred final concentration</p><p>(must be 8-40 mg/mL of ceftazidime)</p></td></tr></tbody></table><p><sup>1 </sup>Based on ceftazidime component only.<sup> </sup></p><p><sup>2</sup> Dilute to final ceftazidime concentration of 8&nbsp;mg/mL for in-use stability up to 12&nbsp;hours at 2&nbsp;-&nbsp;8&deg;C, followed by up to 4&nbsp;hours at not more than 25&deg;C (i.e. dilute 2&nbsp;g dose of ceftazidime in 250&nbsp;mL, 1&nbsp;g dose of ceftazidime in 125&nbsp;mL, 0.75&nbsp;g dose of ceftazidime in 93&nbsp;mL, etc.). All other ceftazidime concentrations (&gt;&nbsp;8 mg/mL to 40&nbsp;mg/mL) have in-use stability up to 4&nbsp;hours at not more than 25&deg;C.</p><p><sup>3 </sup>Dilute to final ceftazidime concentration &ge; 8 mg/mL to 40 mg/mL for in-use stability up to 6 hours at not more than 25&deg;C.</p><p>&nbsp;</p><p><u>Paediatric</u><u> patients 3 to 12 months of age</u></p><p><em>&nbsp;</em></p><p>NOTE: The following procedure describes the steps to prepare an infusion solution with a final concentration of 20 mg/mL of ceftazidime (sufficient for most scenarios). Alternative concentrations may be prepared, but must have a final concentration range of 8-40 mg/mL of ceftazidime.</p><p>&nbsp;</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp; Prepare the <strong>reconstituted solution</strong> (<strong>167.3 mg/mL</strong> of ceftazidime):</p><p>a)&nbsp;&nbsp;&nbsp;&nbsp; Insert the syringe needle through the vial closure and inject 10&nbsp;mL of sterile water for injections.</p><p>b)&nbsp;&nbsp;&nbsp;&nbsp; Withdraw the needle and shake the vial to give a clear solution.</p><p>c) &nbsp;&nbsp; Insert a gas relief needle through the vial closure <strong>after</strong> the product has dissolved to relieve the internal pressure (this is important to preserve product sterility).</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp; Prepare the <strong>final solution</strong> for infusion to a final concentration of <strong>20 mg/mL</strong> of ceftazidime:</p><p>a)&nbsp;&nbsp;&nbsp;&nbsp; Further dilute the reconstituted solution by transferring an appropriately calculated volume of the reconstituted solution combined with a sufficient volume of diluent (sodium chloride 9&nbsp;mg/mL (0.9%) solution for injection or dextrose 50&nbsp;mg/mL (5%) solution for injection) to an infusion syringe.</p><p>b)&nbsp;&nbsp;&nbsp;&nbsp; Refer to Table 9, 10, or 11 below to confirm the calculations. Values shown are approximate as it may be necessary to round to the nearest graduation mark of an appropriately sized syringe. Note that the tables are NOT inclusive of all possible calculated doses but may be utilised to estimate the approximate volume to verify the calculation.</p><p>&nbsp;</p><p>Table 9: Preparation of Zavicefta (final concentration of 20 mg/mL of ceftazidime) in paediatric patients 3 to 12 months of age with creatinine clearance (CrCL) &gt; 50 mL/min/1.73 m<sup>2</sup></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td><p><strong>Age and Zavicefta Dose (mg/kg)<sup>1</sup></strong></p></td><td><p><strong>Weight (kg)</strong></p></td><td><p><strong>Dose </strong></p><p><strong>(mg ceftazidime)</strong></p></td><td><p><strong>Volume of reconstituted solution to be withdrawn from vial </strong></p><p><strong>(mL)</strong></p></td><td><p><strong>Volume of diluent to add for mixing (mL)</strong></p></td></tr></thead><tbody><tr><td rowspan="8"><p><strong>6 months to </strong></p><p><strong>12 months </strong></p><p><strong>&nbsp;</strong></p><p><strong>50 mg/kg </strong></p><p><strong>of ceftazidime</strong></p></td><td><p>5</p></td><td><p>250</p></td><td><p>1.5</p></td><td><p>11</p></td></tr><tr><td><p>6</p></td><td><p>300</p></td><td><p>1.8</p></td><td><p>13</p></td></tr><tr><td><p>7</p></td><td><p>350</p></td><td><p>2.1</p></td><td><p>15</p></td></tr><tr><td><p>8</p></td><td><p>400</p></td><td><p>2.4</p></td><td><p>18</p></td></tr><tr><td><p>9</p></td><td><p>450</p></td><td><p>2.7</p></td><td><p>20</p></td></tr><tr><td><p>10</p></td><td><p>500</p></td><td><p>3</p></td><td><p>22</p></td></tr><tr><td><p>11</p></td><td><p>550</p></td><td><p>3.3</p></td><td><p>24</p></td></tr><tr><td><p>12</p></td><td><p>600</p></td><td><p>3.6</p></td><td><p>27</p></td></tr><tr><td rowspan="7"><p><strong>3 months to </strong></p><p><strong>&lt; 6 months </strong></p><p><strong>&nbsp;</strong></p><p><strong>40 mg/kg </strong></p><p><strong>of ceftazidime</strong></p></td><td><p>4</p></td><td><p>160</p></td><td><p>1</p></td><td><p>7.4</p></td></tr><tr><td><p>5</p></td><td><p>200</p></td><td><p>1.2</p></td><td><p>8.8</p></td></tr><tr><td><p>6</p></td><td><p>240</p></td><td><p>1.4</p></td><td><p>10</p></td></tr><tr><td><p>7</p></td><td><p>280</p></td><td><p>1.7</p></td><td><p>13</p></td></tr><tr><td><p>8</p></td><td><p>320</p></td><td><p>1.9</p></td><td><p>14</p></td></tr><tr><td><p>9</p></td><td><p>360</p></td><td><p>2.2</p></td><td><p>16</p></td></tr><tr><td><p>10</p></td><td><p>400</p></td><td><p>2.4</p></td><td><p>18</p></td></tr></tbody></table><p><sup>1 </sup>Based on ceftazidime component only.</p><p>&nbsp;</p><p>Table 10: Preparation of Zavicefta (final concentration of 20 mg/mL of ceftazidime) in paediatric patients 3 to 12 months of age with CrCL 31 to 50&nbsp;mL/min/1.73 m<sup>2</sup></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td><p><strong>Age and Zavicefta Dose (mg/kg)<sup>1</sup></strong></p></td><td><p><strong>Weight (kg)</strong></p></td><td><p><strong>Dose</strong></p><p><strong>(mg ceftazidime)</strong></p></td><td><p><strong>Volume of reconstituted solution to be withdrawn from vial</strong></p><p><strong>(mL)</strong></p></td><td><p><strong>Volume of diluent to add for mixing (mL)</strong></p></td></tr><tr><td rowspan="8"><p><strong>6 months to </strong></p><p><strong>12 months </strong></p><p><strong>&nbsp;</strong></p><p><strong>25 mg/kg </strong></p><p><strong>of ceftazidime</strong></p></td><td><p>5</p></td><td><p>125</p></td><td><p>0.75</p></td><td><p>5.5</p></td></tr><tr><td><p>6</p></td><td><p>150</p></td><td><p>0.9</p></td><td><p>6.6</p></td></tr><tr><td><p>7</p></td><td><p>175</p></td><td><p>1</p></td><td><p>7.4</p></td></tr><tr><td><p>8</p></td><td><p>200</p></td><td><p>1.2</p></td><td><p>8.8</p></td></tr><tr><td><p>9</p></td><td><p>225</p></td><td><p>1.3</p></td><td><p>9.6</p></td></tr><tr><td><p>10</p></td><td><p>250</p></td><td><p>1.5</p></td><td><p>11</p></td></tr><tr><td><p>11</p></td><td><p>275</p></td><td><p>1.6</p></td><td><p>12</p></td></tr><tr><td><p>12</p></td><td><p>300</p></td><td><p>1.8</p></td><td><p>13</p></td></tr><tr><td rowspan="7"><p><strong>3 months to </strong></p><p><strong>&lt; 6 months </strong></p><p><strong>&nbsp;</strong></p><p><strong>20 mg/kg </strong></p><p><strong>of ceftazidime</strong></p></td><td><p>4</p></td><td><p>80</p></td><td><p>0.48</p></td><td><p>3.5</p></td></tr><tr><td><p>5</p></td><td><p>100</p></td><td><p>0.6</p></td><td><p>4.4</p></td></tr><tr><td><p>6</p></td><td><p>120</p></td><td><p>0.72</p></td><td><p>5.3</p></td></tr><tr><td><p>7</p></td><td><p>140</p></td><td><p>0.84</p></td><td><p>6.2</p></td></tr><tr><td><p>8</p></td><td><p>160</p></td><td><p>1</p></td><td><p>7.4</p></td></tr><tr><td><p>9</p></td><td><p>180</p></td><td><p>1.1</p></td><td><p>8.1</p></td></tr><tr><td><p>10</p></td><td><p>200</p></td><td><p>1.2</p></td><td><p>8.8</p></td></tr></tbody></table><p><sup>1 </sup>Based on ceftazidime component only.</p><p>&nbsp;</p><p>Table 11: Preparation of Zavicefta (final concentration of 20 mg/mL of ceftazidime) in paediatric patients 3 to 12 months of age with CrCL 16 to 30&nbsp;mL/min/1.73 m<sup>2</sup></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td><p><strong>Age and Zavicefta Dose (mg/kg)<sup> 1</sup></strong></p></td><td><p><strong>Weight (kg)</strong></p></td><td><p><strong>Dose</strong></p><p><strong>(mg ceftazidime)</strong></p></td><td><p><strong>Volume of reconstituted solution to be withdrawn from vial</strong></p><p><strong>(mL)</strong></p></td><td><p><strong>Volume of diluent to add for mixing (mL)</strong></p></td></tr></thead><tbody><tr><td rowspan="8"><p><strong>6 months to </strong></p><p><strong>12 months </strong></p><p><strong>&nbsp;</strong></p><p><strong>18.75 mg/kg </strong></p><p><strong>of ceftazidime</strong></p></td><td><p>5</p></td><td><p>93.75</p></td><td><p>0.56</p></td><td><p>4.1</p></td></tr><tr><td><p>6</p></td><td><p>112.5</p></td><td><p>0.67</p></td><td><p>4.9</p></td></tr><tr><td><p>7</p></td><td><p>131.25</p></td><td><p>0.78</p></td><td><p>5.7</p></td></tr><tr><td><p>8</p></td><td><p>150</p></td><td><p>0.9</p></td><td><p>6.6</p></td></tr><tr><td><p>9</p></td><td><p>168.75</p></td><td><p>1</p></td><td><p>7.4</p></td></tr><tr><td><p>10</p></td><td><p>187.5</p></td><td><p>1.1</p></td><td><p>8.1</p></td></tr><tr><td><p>11</p></td><td><p>206.25</p></td><td><p>1.2</p></td><td><p>8.8</p></td></tr><tr><td><p>12</p></td><td><p>225</p></td><td><p>1.3</p></td><td><p>9.6</p></td></tr><tr><td rowspan="7"><p><strong>3 months to </strong></p><p><strong>&lt; 6 months </strong></p><p><strong>&nbsp;</strong></p><p><strong>15 mg/kg </strong></p><p><strong>of ceftazidime</strong></p></td><td><p>4</p></td><td><p>60</p></td><td><p>0.36</p></td><td><p>2.7</p></td></tr><tr><td><p>5</p></td><td><p>75</p></td><td><p>0.45</p></td><td><p>3.3</p></td></tr><tr><td><p>6</p></td><td><p>90</p></td><td><p>0.54</p></td><td><p>4</p></td></tr><tr><td><p>7</p></td><td><p>105</p></td><td><p>0.63</p></td><td><p>4.6</p></td></tr><tr><td><p>8</p></td><td><p>120</p></td><td><p>0.72</p></td><td><p>5.3</p></td></tr><tr><td><p>9</p></td><td><p>135</p></td><td><p>0.81</p></td><td><p>6</p></td></tr><tr><td><p>10</p></td><td><p>150</p></td><td><p>0.9</p></td><td><p>6.6</p></td></tr></tbody></table><p><sup>1 </sup>Based on ceftazidime component only.</p><p>&nbsp;</p><p><u>Paediatric patients from birth (including preterm) to &lt; 3 months of age:</u></p><p><strong>&nbsp;</strong></p><p>NOTE: The following procedure describes the steps to prepare a stock infusion solution with a final concentration of 10 mg/mL of ceftazidime appropriate for administering doses under 250 mg to paediatric patients from birth (including preterm) to &lt; 3 months of age. Alternative concentrations may be prepared, but must have a final concentration range of 8-40 mg/mL of ceftazidime.</p><p>&nbsp;</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp; Prepare the <strong>reconstituted solution (167.3 mg/mL</strong> of ceftazidime):</p><p>a)&nbsp;&nbsp;&nbsp;&nbsp; Insert the syringe needle through the vial closure and inject 10 mL of sterile water for injections.</p><p>b)&nbsp;&nbsp;&nbsp;&nbsp; Withdraw the needle and shake the vial to give a clear solution.</p><p>c)&nbsp;&nbsp;&nbsp;&nbsp; Insert a gas relief needle through the vial closure <strong>after</strong> the product has dissolved to relieve the internal pressure (this is important to preserve product sterility).</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp; Prepare the <strong>final stock solution</strong> for infusion to a final concentration of <strong>10 mg/mL</strong> of ceftazidime:</p><p>a)&nbsp;&nbsp;&nbsp;&nbsp; Further dilute the reconstituted solution by transferring 3 mL of the reconstituted solution to an infusion bag or a syringe containing 47 mL of diluent (sodium chloride 9 mg/mL (0.9%) solution for injection or dextrose 50 mg/mL (5%) solution for injection) to provide a final volume of 50 mL.</p><p>b)&nbsp;&nbsp;&nbsp;&nbsp; Mix thoroughly (e.g. gently invert the infusion bag or using a syringe connector gently pass the solution back and forth at least 5 times between 2 syringes).</p><p>c)&nbsp;&nbsp;&nbsp;&nbsp; Transfer an appropriate volume of the <strong>10 mg/mL</strong> of ceftazidime stock solution to an infusion syringe. Refer to Table 12 below for the volume of the stock solution to transfer to the infusion syringe to be administered. Values shown are approximate as it may be necessary to round to the nearest graduation mark of an appropriately sized syringe.<br />Note that the tables are NOT inclusive of all possible calculated doses but may be utilised to estimate the approximate volume to verify the calculation.</p><p>&nbsp;</p><p>Table 12: Zavicefta dosing in paediatric patients from birth (including preterm) to &lt; 3 months of age using a 50 mL stock solution of Zavicefta (final concentration of 10 mg/mL of ceftazidime) prepared with 3 mL reconstituted solution withdrawn from the vial and added to 47 mL diluent.</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td><p>Age and Zavicefta dose (mg/kg)<sup>1</sup></p></td><td><p>Weight (kg)</p></td><td><p>Dose</p><p>(mg ceftazidime)</p></td><td><p>Volume of 10 mg/mL (ceftazidime) stock solution to be administered (mL)</p></td></tr><tr><td rowspan="11"><p>Full term infants (gestation &ge; 37&nbsp;weeks) from &gt; 28&nbsp;days to &lt;&nbsp;3&nbsp;months</p><p>&nbsp;</p><p>OR</p><p>&nbsp;</p><p>Preterm infants from &gt;&nbsp;44&nbsp;weeks to &lt;&nbsp;53 weeks PMA</p><p>&nbsp;</p><p><strong>30 mg/kg of ceftazidime</strong></p></td><td><p>3</p></td><td><p>90</p></td><td><p>9</p></td></tr><tr><td><p>3.5</p></td><td><p>105</p></td><td><p>10.5</p></td></tr><tr><td><p>4</p></td><td><p>120</p></td><td><p>12</p></td></tr><tr><td><p>4.5</p></td><td><p>135</p></td><td><p>13.5</p></td></tr><tr><td><p>5</p></td><td><p>150</p></td><td><p>15</p></td></tr><tr><td><p>5.5</p></td><td><p>165</p></td><td><p>16.5</p></td></tr><tr><td><p>6</p></td><td><p>180</p></td><td><p>18</p></td></tr><tr><td><p>6.5</p></td><td><p>195</p></td><td><p>19.5</p></td></tr><tr><td><p>7</p></td><td><p>210</p></td><td><p>21</p></td></tr><tr><td><p>7.5</p></td><td><p>225</p></td><td><p>22.5</p></td></tr><tr><td><p>8</p></td><td><p>240</p></td><td><p>24</p></td></tr><tr><td rowspan="18"><p>Full term neonates (gestation &ge;&nbsp;37&nbsp;weeks) from birth to &le;&nbsp;28 days</p><p>&nbsp;</p><p>OR</p><p>&nbsp;</p><p>Preterm neonates and infants from 26 to &le;&nbsp;44&nbsp;weeks PMA</p><p>&nbsp;</p><p><strong>20 mg/kg of ceftazidime</strong></p></td><td><p>0.8</p></td><td><p>16</p></td><td><p>1.6</p></td></tr><tr><td><p>1</p></td><td><p>20</p></td><td><p>2</p></td></tr><tr><td><p>1.2</p></td><td><p>24</p></td><td><p>2.4</p></td></tr><tr><td><p>1.4</p></td><td><p>28</p></td><td><p>2.8</p></td></tr><tr><td><p>1.6</p></td><td><p>32</p></td><td><p>3.2</p></td></tr><tr><td><p>1.8</p></td><td><p>36</p></td><td><p>3.6</p></td></tr><tr><td><p>2</p></td><td><p>40</p></td><td><p>4</p></td></tr><tr><td><p>2.2</p></td><td><p>44</p></td><td><p>4.4</p></td></tr><tr><td><p>2.4</p></td><td><p>48</p></td><td><p>4.8</p></td></tr><tr><td><p>2.6</p></td><td><p>52</p></td><td><p>5.2</p></td></tr><tr><td><p>2.8</p></td><td><p>56</p></td><td><p>5.6</p></td></tr><tr><td><p>3</p></td><td><p>60</p></td><td><p>6</p></td></tr><tr><td><p>3.5</p></td><td><p>70</p></td><td><p>7</p></td></tr><tr><td><p>4</p></td><td><p>80</p></td><td><p>8</p></td></tr><tr><td><p>4.5</p></td><td><p>90</p></td><td><p>9</p></td></tr><tr><td><p>5</p></td><td><p>100</p></td><td><p>10</p></td></tr><tr><td><p>5.5</p></td><td><p>110</p></td><td><p>11</p></td></tr><tr><td><p>6</p></td><td><p>120</p></td><td><p>12</p></td></tr></tbody></table><p><sup>1&nbsp;</sup>Based on ceftazidime component only.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MARKETING AUTHORISATION HOLDER
Pfizer Ireland Pharmaceuticals
Ireland

MANUFACTURER
ACS Dobfar S.p.A, 
Italy

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                	October 2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>